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Abstract 
 
Parkinson's disease (PD) is a slowly progressive degenerative disorder of the central 
nervous system that is classically defined in terms of motor symptoms consequent to 
degeneration of specific subsets of mesencephalic dopaminergic (DA) cells within 
substantia nigra (SN) pars compacta. No pharmacological treatment is currently 
available to slow or arrest the neurodegenerative process. Furthermore, accurate 
early diagnosis suffers from the lack of reliable biomarkers.  
By the time motor symptoms appear, PD patients have already lost 60-70% of DA-
producing cells (Dauer & Przedborski 2003) proving that sporadic PD is diagnosed 
many years after the onset. It is therefore reasonable to expect that potential 
pharmacological treatments could be more effective if patients can benefit from it in 
the premotor phase. 
Given the systemic nature of the disease, it is not surprising that many alterations of 
blood physiology have been described in PD patients (Kim et al., 2004; Shults and 
Haas, 2005; Bongioanni et al., 1996; Migliore et al., 2002; Petrozzi et al., 2002; 
Salman et al., 1999; Larumbe et al., 2001; Bessler et al., 1999). In this context, a 
blood test to predict PD would impact the ability to identify new treatments for this 
incurable disease. Furthermore, it could be applied to a large number of individuals 
since blood is commonly used in diagnostics for being easily accessible.  
Gene expression analysis is a powerful tool to study complex diseases such PD and it 
has been extensively employed to find peripheral biomarkers (Papapetropoulos et al., 
2007).  
In the laboratory of Prof Gustincich, in collaboration with Dr Carninci at RIKEN, 
Yokohama, Japan, nanoCAGE technology has been previously used to find 
alterations in the blood transcriptome of 20 drug naïve de novo PD patients 
compared to 20 Healthy Controls (HC). NanoCAGE allows the identification of 
Transcription Start Sites (TSSs) and therefore of the associated promoters providing 
an unbias quantitative description of the cellular transcriptome targeting virtually any 
RNA molecule present in the sample. 
The most up-regulated nanoCAGE tag in PD patients is located in the third intron of 
the gene Nitrogen Permease Regulator Like Protein 3 (Nprl3). 
Nprl3 gene lies on the telomeric region of human chromosome 11 and contains in its 
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intron the major regulator elements of α globin (Hughes et al., 2005).  
Neklesa and Davis in 2009 (in yeast) and Bar-Peled et al. in 2013 (in mammals) 
proved that Nprl3 is a component of a protein complex that inhibits mTORC1 
activity.  
In eukaryotes TOR is the major sensor of nutrients, energy and stress. Alterations in 
its pathway have been correlated with diseases and conditions where growth and 
homeostasis are compromised such as cancer, metabolic diseases and aging. 
The aim of my PhD thesis was to identify the full-length transcript associated to the 
nanoCAGE tag, validate it, and to test whether it may represent a peripheral 
biomarker of PD. 
Taking advantage of rapid amplification of cDNA ends (RACE) assay, I 
demonstrated that the tag represents an alternative Transcription Start Site of Nprl3 
(TagNprl3). It is associated to a TCT motif (YC+1TYTYY) for initiation of 
transcription, which has been found to be specific for ribosomal protein coding genes 
and those involved in protein synthesis. The tag maps to a 29nt minisatellite that is 
found repeated 16 times in the reference genome. High-tag expression is associated 
to an allelic genomic variant of 13 repeats. To our knowledge this is the first time 
that a minisatellite variant is both a TSS and an expression quantitative trait locus 
(eQTL). 
Unfortunately, high TagNprl3 expression resulted not to be correlated to PD but to 
heterozygosity. Furthermore, allelic frequencies were not correlated to PD.  
I then showed that TagNprl3 is expressed in red blood cells (RBCs) both at mRNA 
and protein levels giving rise to an isoform truncated at the N-terminal. This is able 
to interact with its protein partner Nprl2 and its overexpression inhibits cell 
proliferation.  
This work provides hints for Nprl3 protein function in blood and may suggest a 
testable hypothesis linking mTOR activity to genomic polymorphisms in modifier 
genes.  
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Introduction 
 
Gene expression regulation 
The fine regulation of gene expression in a living organism is extremely complex 
and requires several players for its correct tuning in time and space, which is 
fundamental for normal development and maintenance. Slight alterations could have 
dramatic cascade effects, from cellular level to whole organism, that can lead to loss 
of homeostasis and then to disease (Chen et al., 2008; Cookson et al., 2009; Emilsson 
et al., 2008). 
Cells control and regulate their gene expression through different mechanisms, 
which can be summarized in six steps: 
1) Epigenetics 
First defined by Conrad Waddington (1905–1975) as “the branch of biology 
which studies the causal interactions between genes and their products, which 
bring the phenotype into being” (Goldberg et al., 2007) and comprehends all the 
heritable changes in gene expression that occur without DNA sequence alteration 
(Bird, 2007). 
The main epigenetic modifications are the chemical changes to cytosine residues 
of DNA (DNA methylation) and to histone proteins (Bernstein et al., 2007). 
Epigenetics control gene expression by changing chromatin structure: accessible 
chromatin is associated with actively transcribed gene and, viceversa, 
inaccessible chromatin is often associated with silent genes. 
2) Transcription 
RNA polymerase is the main player in the transcription step that is modulated by 
several proteins called “activators” and “repressors” along with others 
transcription factors (TF). They can bind specific DNA sequences, namely 
enhancers and promoters, regulating gene expression through different 
mechanisms, for example stabilizing or blocking RNA polymerase, influencing 
histone protein modifications, recruiting other protein complexes. Furthermore, 
TF activity is in turn modulated via post-transcriptional modifications (PTMs) by 
specific enzymes in response to cellular stimuli. 
3) Post-translational modification (PTMs) 
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PTMs convert a precursor messenger RNA (mRNA) into a mature mRNA and 
they are essential for a correct protein translation. They include splicing, 5’-
capping and 3’-polyadenylation providing intron excision and RNA stabilization. 
RNA editing are rare events but there are evidences for which they can contribute 
to mRNA degradation (Agranat et al., 2008). 
4) RNA transport 
To regulate spatial gene expression, mRNAs are transported, localized and 
locally translated in several eukaryotic cell types (Kindler et al., 2005) and 
translation is repressed during transport to prevent ectopic expression (Kwon et 
al., 1999). 
5) Translation 
Translation is carried out by the ribosomes and is divided into three steps called 
initiation, elongation and termination. Two general modes of control can occur: 
global translation, in which the translation of most mRNAs in the cell is 
regulated, or mRNA-specific translation, in which a defined group of mRNA is 
affected (Gebauer and Hentze, 2004). 
6) mRNA degradation 
Eukaryotic mRNAs have a half-life that spans from few minutes to several days 
(Yu and Russell, 2001) and this strongly influences the rate of protein synthesis. 
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Figure 1. Different steps in the gene expression pathway (Orphanides and Reinberg, 2002). 
 
 
Gene expression profiling 
To identify the pattern of expression in a cell in a defined time and condition, gene 
expression profiling techniques have been developed.  
Among them, DNA microarrays take advantage of DNA probes targeting annotated 
genes measuring their relative activity and, on the other hand, sequence-based 
techniques allow profiling of all active genes using a hypothesis-neutral approach. 
However, despite the enormous potential of these technologies, the finding of an 
appropriate control in expression comparison, the heterogeneity of tissues and the 
statistical analysis of arrays represent challenging roadblocks to a faithful 
representation of biological activity. Finally, gene expression profiles must be also 
validated using complementary technologies as RT-PCRs (King and Sinha, 2001). 
 
 
Introduction	  
	   6	  
NanoCAGE 
The use of nucleic acid sequencing has increased exponentially thanks to the new 
technologies that allow cheaper and faster results. 
Next-generation sequencing (NGS) platforms can perform massively parallel 
sequencing delivering an entire genome in less than one day (Grada and Weinbrecht, 
2013).  
These technologies allow an unbiased description of the cellular transcriptome 
targeting virtually any RNA molecule present in the sample. 
Tagging technologies, like SAGE and nanoCAGE, aim at the description of new 
transcripts types and their transcription start sites (TSSs). 
Cap-Analysis of Gene Expression (CAGE) is a tagging technique developed at the 
RIKEN Institute in Japan. It is based on the production of short tag sequences close 
to the 5’-end of the transcript and the ligation of tags into groups of concatamers, 
followed by cloning and sequencing of ligation products (Gustincich et al., 2006; 
Kodzius et al., 2006; Shiraki et al., 2003). Through statistical calculations, assessing 
the number of tags related to a specific transcripts normalized per million of 
sequenced tags (tags per million, TPM), the information derived by CAGE data are 
quantitative. 
The advantages of CAGE over other methodologies such as microarrays in 
identifying new promoters and new TSSs are becoming more evident as the 
sequencing technologies become more affordable. A major limitation of CAGE was 
the need for a large amount of starting RNAs. Recent advancements in 5’-end 
tagging and sequencing have made possible the development of a new technology of 
the CAGE type for total RNA quantities as low as 50 nanograms. This new 
technique, named “nanoCAGE”, has been developed in the laboratories of S. 
Gustincich (SISSA) and P. Carninci (RIKEN). It is very powerful in the analyses of 
transcriptomes and promotomes of small RNA samples, for example those purified 
with Laser Capture Microdissection, Fluorescence-Activated Cell Sorters (FACS) 
and similar technologies.  
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TSS complexity 
The complexity of transcription initiation has been historically difficult to grasp for 
the limits of the available technologies in pre-genomics era.  
Differential TSS usage gives rise to a diverse repertory of 5’UTRs that may regulate 
mRNA translation, localization and stabilization.  
A well-known example is the neurotrophin brain-derived neurotrophic factor 
(BDNF) gene that is characterized by eleven different 5’UTRs, generated by nine 
exons with different TSSs. BDNF is essential for neuronal survival, differentiation, 
and plasticity and is widely expressed in the brain. The laboratory of Prof Tongiorgi 
demonstrated that different TSS usage determines different subcellular localization 
of BDNF mRNAs that can be directed to distal dendrites or to soma and proximal 
dendrites (Chiaruttini et al., 2008; Pattabiraman et al., 2005; Tongiorgi et al., 2004). 
For many years the study of differential TSS usage was carried out by analysing one 
gene at a time.  
The purpose of CAGE developers was to create a technology to map TSSs and 
promoters at a genome-wide levels and that can be exploited to monitor 
transcriptional control in different tissues, cells and conditions. Deep-sequencing is 
necessary to detect all the active promoters in a given sample; simultaneously, the 
study of alternative promoters allow us to understand how a gene responds to distinct 
regulatory inputs, how mRNAs and protein isoforms are expressed in time and space 
and finally how gene isoforms that are preferentially expressed in a given tissue can 
be selectively targeted (Valen et al., 2009). 
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Figure 2. Example of differential TSSs usage in different brain tissues. A) The Venn diagram 
reports the number of genes that have at least one preferentially expressed promoter (PEP) in 
the four brain tissues or any combination PEPs of the four tissues. B) The Dlgap1 gene has four 
PEPs, one from each brain tissue (Valen et al., 2009). 
 
 
Expression Quantitative Trait Loci (eQTL) 
The development of techniques to study expression profiles has led to a better 
understanding of the biological processes that are implicated in human complex 
diseases. However, these approaches lead to analyses that are limited to the genome 
output (the transcribed RNA), omitting the genome variation that could be 
responsible for expression variations. 
A genome-wide association study (GWAS) is an analysis on the genetic variants of a 
population to find variants associated to traits. 
The aim of GWASs is usually to find traits associated to human diseases by 
analysing differences in Single Nucleotide Polymorphisms (SNPs) that represent 
about 90% of sequence variants in humans (Collins et al., 1998). 
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However, the risk of false-positive results, insufficient sample size, the biases due to 
case and control selection, the insensitivity to rare and structural variants and the lack 
of information on gene function are common problems (Pearson and Manolio, 2008). 
To overcome the limitations of the two methodologies, in 2001 Jansen and Nap 
showed that by correlating genetic polymorphisms with expression profiles (RNA, 
protein or metabolites) it is possible to identify quantitative trait loci (QTL), 
introducing the concept of “genetical genomics”. 
In particular, mRNA levels are easily quantified by using microarrays and next 
generation sequencing (NGS) allowing the mapping of expression QTL (eQTL) that 
helped the dissection of the genetic basis of gene expression. 
Genome-wide eQTL mapping has been conducted in many species (Brem et al., 
2002; Rockman and Kruglyak, 2006; Schadt et al., 2008) and indeed is a powerful 
mean to study human complex diseases (Emilsson et al., 2008; Huang et al., 2007; 
Schadt et al., 2008; Zhong et al., 2010) that are caused by many genes, involving 
various biological pathways and varying in severity of symptoms and age of onset 
(Tabor et al., 2002). 
eQTLs have been subdivided into cis-eQTLs and trans-eQTLs: in the former the 
genetic variant is located near the affected gene, in the latter is distant or on a 
different chromosome. Cis-eQTLs have usually higher effects on gene expression 
and are found close to the transcription start site (TSS) or in the genic sequence, 
probably altering transcription factors (TFs) binding or other cis regulatory elements. 
On the other hand, trans-eQTLs have usually smaller effect size and therefore they 
are difficult to detect (Westra and Franke, 2014). 
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Figure 3.  eQTLs can be either local effects (cis-eQTL), or distant, indirect effects (trans-eQTL) 
(Westra and Franke, 2014). 
 
 
Repetitive elements in the mammalian genome 
Despite being considered as “junk DNA” for many years, repetitive elements (RE) in 
the mammalian genome play an important functional role in genome organization 
and stability. 
RE represent 50-70% of human genome and are simply defined as DNA sequences 
repeated multiple times (Padeken et al., 2015). They are classified into two groups, 
based on their origin, as follows: 
1) Tandem repeats 
Tandem repeats are thought to origin by improper DNA replication and are 
highly variable among individuals. 
They are defined as pattern of DNA repeated one adjacent to another in a head to 
tail fashion. They can be classified based on the size of the repeated block. 
Microsatellites have a 2-5 bp core unit spanning up to hundreds of base pairs and 
are usually found dispersed throughout the genome. Minisatellites, also called 
Variable Number of Tandem Repeats (VNTR), have a unit length of 10-60 bp 
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with a conserved core sequence of 10-15 bp, spanning 0.1-15 kb and are usually 
found on telomeric regions. Satellite (centromeric and telomeric) tandem repeats 
have usually a 5-171 bp core unit and they can stretch to more than 100 kb 
(Padeken et al., 2015; Strachan and Read, 2004). 
2) Transposable elements 
As suggested by their name, transposable elements can mobilize and change their 
position in the genome and are subdivided into DNA transposons and RNA 
transposons depending on the intermediate form that is used for transposition. 
 
 
Figure 4. Schematic representation of RE classes, their distribution and their structural 
hallmarks (adapted from Padeken et al., 2015). 
 
 
Minisatellites and human diseases 
Wyman and White discovered the first minisatellite sequence in 1980. The majority 
of them are GC rich with a strong strand asymmetry exhibiting hypervariability and a 
high degree of polymorphism. However, most minisatellites are quite stable except 
few loci, called hypermutable minisatellites (Denoeud et al., 2003). 
For this reason, they revealed to be useful as DNA fingerprinting in forensic 
applications, as first proposed by Jeffreys et al. in 1985. Nonetheless, the very nature 
of minisatellites makes them unsuitable for genotyping on array platforms, as it was 
possible for SNPs, because of the high variable number of repeats (Brookes, 2013). 
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For this reason, a genome-wide approach to study minisatellite variants correlated to 
human diseases was not possible although many studies have shown their important 
biological functions, such as regulating the level of expression of the nearby genes. 
Based on their position, minisatellite polymorphisms are subdivided into three 
classes, here described.  
1) Coding polymorphisms 
Minisatellites polymorphisms occurring in the coding region of a gene are the 
best candidates for a functional activity, since they are translated into protein. 
One example is the minisatellite present in the third exon of the Dopamine 
Receptor D4 (DRD4) gene that has been associated with Attention Deficit 
Hyperactive Disorder (ADHD), response to clozapine in schizophrenia treatment 
(Shaikh et al., 1993) and other neurological disorders (Figure 5). The 48 bp 
minisatellite ranges from 2 to 11 repeats and, once translated, each tandem repeat 
adds 16 aminoacids to the third cytoplasmic loop of the protein (Chio et al., 
1994; Van Tol et al., 1991). Albeit the function of the receptor is only partially 
influenced by the number of repeats and only in certain conditions, different 
DRD4 variants display differential sensitivity to dopamine chaperone effect in 
the cell (Van Craenenbroeck et al., 2005). 
2) Promoter polymorphisms 
Transcriptional machinery binding to promoter is strongly influenced by its 
sequence and therefore minisatellites could have an important impact on the level 
of expression. Many polymorphisms have been found in promoter regions and 
some examples are the Serotonin Transporter (5HTT/SLC6A4) gene, the Insulin 
(INS) gene and the Monoamine Oxidase A (MAOA) gene. 
The 20-23 bp of 5HTT promoter are repeated 14 or 16 times and the short variant 
of the polymorphism reduces the transcriptional efficiency and can be partially 
related to anxiety-related traits (Lesch et al., 1996) which are related to increased 
risk of depression (Lotrich and Pollock, 2004). Moreover Pezawas and 
colleagues in 2005 showed with morphometric analysis that short-allele carriers 
have reduced gray matter volume and connectivity in limbic regions critical for 
processing of negative emotions, particularly perigenual cingulate and amygdala 
(Pezawas et al., 2005). 
Introduction	  
	   13	  
The 14-15 bp tandem repeat of INS promoter is present in variable number and in 
particular three classes of alleles have been defined based on its size: class I 
consists of 28-44 repeats, class II 45-137 and class III 138-159. 
Class I alleles predispose in a recessive way to Type 1 Diabetes (T1D), while 
class III alleles are dominantly protective (Bennett et al., 1997).  
A possible mechanism for this protective effect is the tolerance induction to 
insulin epitopes achieved by higher levels of insulin in the thymus promoted by 
class III alleles (Durinovic-Belló et al., 2005). On the contrary, class I alleles 
might predispose individuals to type 1 diabetes by lowering insulin expression in 
the thymus and rendering less tolerance induction (Cai et al., 2011). 
MAOA gene has a 30 bp repeat sequence in the promoter region that is present 2, 
3, 3.5, 4, 5 times and the variants are respectively called 2R, 3R, 3.5R, 4R, 5R. 
Alleles 3.5R and 4R are transcribed 2-10 times more efficiently than 3R (Sabol et 
al., 1998). MAOA minisatellite has been associated with several behavioural 
disorders, including bipolar disorder, impulsivity and antisocial behaviour and in 
females the longer alleles with panic disorder (Brookes, 2013). 
3) Other polymorphisms 
Minisatellite polymorphisms can finally be present in intronic and untranslated 
regions of genes influencing RNA splicing, localization, stability and 
translational efficiency. An example is the Dopamine Transporter gene 
(DAT1/SLC6A3), which has a 3’untranslated region (UTR) minisatellite of 40 
bp repeated 7-11 times. 
The minisatellite allele can alter the level of expression of DAT1 although 
discordant data have been reported (Brookes, 2013). 
The 10-repeat variant is abnormally efficient at the re-uptake process and 
underactive in the dopaminergic mesocorticolimbic and nigrostriatal pathways, 
suggesting reduced dopamine in mesolimbic and striatal pathways that are 
commonly implicated in major depressive disorder (MDD) and in ADHD (Gatt 
et al., 2015). 
Nevertheless, the function of minisatellite polymorphisms present in non-coding 
regions is usually elusive and the alteration of nearby genes could be determined 
by the number of repeats and by the proteins that can target them. An example is 
the alpha-thalassaemia/mental retardation syndrome X-linked (ATRX) protein 
that alters gene expression by binding to G-rich tandem repeats. Law et al. in 
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2010 found that, in erythroid cells, ATRX mostly localizes on ψζ VNTR repeat 
in the alpha globin gene locus and, when it is mutated, induces down-regulation 
of the nearby genes explaining why patients exhibit alpha-thalassemia (Law et 
al., 2010). 
Moreover, they demonstrated that patients with the same ATRX mutation could 
exhibit different severities of the disease because the inhibition is proportional to 
the repeat expansion. 
 
 
Figure 5. The three classes of minisatellite polymorphisms, based on their position relative to the 
influenced gene. 
 
 
Parkinson’s disease 
Parkinson’s disease (PD) is a common, complex, progressive neurodegenerative 
disorder first described in 1817 by doctor James Parkinson on his “An Essay on the 
Shaking Palsy” (Parkinson, 1817). The characterization of the pathology is still 
ongoing given its heterogeneity and complexity. While it was considered an 
exclusive motor disease for many years, recently numerous non-motor symptoms 
have been associated to PD and they can precede the motor onset by more than a 
decade, encouraging the seek of precocious markers of the pathology. In fact, an 
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early and better diagnosis is fundamental for PD diagnosis, giving the possibility to 
discover effective pharmacological treatments at the first stages of the disease in 
perspective of slowing its progression and providing a better and longer life for 
patients.  
While its etiology is still unknown, PD is believed to develop from a complicated 
interplay between genetics and environment.  
Importantly, PD remains with no cure and the existing therapies act only to alleviate 
symptoms. 
 
 
PD clinical aspects 
During the 1950s and 1960s, Arvid Carlsson (Nobel Prize in 2000) demonstrated that 
PD patients showed a massive loss of Dopamine (DA) in the brain, which can be 
clinically reverted by treatment with levodopa. 
Nowadays PD is the second most common progressive neurodegenerative disorder 
(six million patients worldwide) after Alzheimer’s disease (AD). It affects 1-2 % of 
all individuals above the age of 65 years old, increasing to 4-5% by the age of 85. 
PD is characterized by six cardinal features: tremor at rest, rigidity, bradykinesia, 
hypokinesia and akinesia, flexed posture of neck, trunk and limbs, loss of postural 
reflexes and freezing phenomenon. The early symptoms of PD are usually alleviated 
by the treatment with levodopa and DA agonists. As PD advances from year to year, 
late symptoms such as flexed posture, loss of postural reflexes and freezing 
phenomenon as well as bradykinesia become resistant to pharmacological treatments. 
While motor symptoms dominate PD clinical features, many patients show non-
motor symptoms. These include fatigue, depression, anxiety, sleep disturbances, 
constipation, bladder and other autonomic disturbances (sexual and gastrointestinal), 
sensory complaints, decreased motivation, apathy and a decline in cognition that can 
progress to dementia (Braak et al., 2004). 
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Figure 6. PD progression and relative clinical symptoms (Kalia and Lang, 2015). 
 
 
Neuropathological features of PD 
Analysis of post mortem PD brains show three major pathological features: 
depigmentation of the substantia nigra (SN) caused by the loss of DA neurons 
projecting in the striatum (principal cause of PD motor symptoms); presence of 
intraneuronal inclusions known as Lewy bodies within the surviving neurons of the 
SN as well as other brain regions and iron deposits. 
The following features are considered PD hallmarks:  
1) Loss of midbrain DA neurons and consequent dopamine depletion in the 
striatum 
Motor dysfunctions are key features of PD. Voluntary movements originate at 
motor cortex level: signals are sent through the encephalic trunk (mesencephalon, 
pons and medulla) to the brain stem and spinal cord. These signalling pathways 
are controlled by different sub-cortical structures (thalamus, putamen and 
subthalamic nuclei) that modulate movements thanks to a complex network of 
excitatory and inhibitory signals. These nuclei are, in turn, innervated and 
modulated by ventral midbrain DA neurons, subdivided into three main groups: 
A8 (retrorubral field; RRF), A9 (substantia nigra pars compacta SNc), and A10 
(ventral tegmental area; VTA). The sensorimotor striatum involved in control of 
movement (putamen) is mainly innervated by DA cells of the ventral SNc 
whereas the limbic ventral striatum and the thalamus are targeted preferentially 
by VTA and dorsal SNc neurons. The characteristic motor symptoms of PD are 
due to the alteration of this movement control system, in particular, to the 
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selective, slow and progressive loss of DA neurons in the SNc. Their loss leads to 
a profound reduction in striatal dopamine that provokes an unbalance between 
excitatory and inhibitory trasmission in the basal ganglia-thalamocortical 
“motor” circuit (Dauer and Przedborski, 2003). The decreased striatal dopamine 
causes increased inhibitory output from the globus pallidus internal segment and 
substantia nigra pars reticulata (GPi/SNr) that, in turn, suppresses movement. 
On one hand, decreased striatal dopamine stimulation causes the direct reduction 
of the inhibition of the GPi/SNr; on the other hand, decreased dopamine 
inhibition causes increased inhibition of the globus pallidus external segment 
(GPe), resulting in blocking the inhibition of the subtalamic nucleus (STN). 
Increased STN output increases GPi/SNr inhibitory output to the thalamus that 
cannot regulate the activity of the motor cortex any longer. 
The pattern of progressive cell loss is not homogeneous, but rather displays a 
complex topographical and regional organization: the degeneration starts from 
the most lateral part of SNc and spreads to the most medialis region. 
Furthermore, nigrostriatal projections to the putamen are more sensitive than 
those to caudate and nucleus accumbens regions, whereas VTA projections to the 
ventral striatum are selectively spared in PD patients. 
While loss of the nigral DA neurons and terminals are responsible for the 
movement disorders associated to PD, it has become clear that additional 
neuronal populations throughout the brain are also affected in the disease (Braak 
et al., 2004). 
2) Lewy bodies 
Typical pathological hallmarks of the disease are Lewy Bodies (LBs), discovered 
in 1919 by Trétiakoff, and dystrophic neuritis, also called Lewy Neurites (LNs) 
first described by Friederich Lewy in the dorsal motor nucleus of the vagus nerve 
and in the substantia innominata from patients with PD. 
LBs and LNs are present in PD patients’ brains in some of the surviving DA 
neurons and in other regions like dorsal motor nucleus of the vagus, locus 
ceruleus, thalamus, amygdala, olfactory nuclei, pediculopontine nucleus, and 
cerebral cortex. In late stages of PD, when patients manifest all motor and 
cognitive clinical symptoms, inclusion bodies decorate the entire neocortex 
comprising the sensory association area (Braak et al., 2004). LBs are round 
cytoplasmatic eosinophilic inclusions, 5–25 µm in diameter. The ultrastructure 
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show that they are composed of a dense core of filamentous and granular 
material, surrounded by radially orientated filaments of 10–20 nm in diameter. 
LBs are composed by the accumulation of cytoplasmic aggregates containing a 
variety of proteins, like α-synuclein, the major component, parkin and UCHL1 
(genes whose mutations have been correlated with PD) and many others like 
Hsp70, ubiquitin and components of the proteasome (Spillantini and Goedert, 
2013). 
LNs are abnormal neurites that contain the same proteins and abnormal filaments 
found in LBs. The mechanism causing the abnormal accumulation of proteins in 
LBs and LNs is not yet known and their toxic or protective role in 
neurodegenerative process is still matter of debate because until now there is no 
clear correlation between inclusion formation and neuronal cell death. If LBs are 
considered toxic, cytoplasmic protein aggregates may interfere with intracellular 
trafficking or sequestrate proteins important for cell survival. On the other hand, 
LBs are present in surviving cells that seem to be healthier, by morphological and 
biochemical analysis, than neighbouring cells (Tompkins et al., 1997). Moreover, 
LBs have been also found in people without evident neuronal loss or clinical 
signs of PD, so they could be a protective structure in which proteins accumulate 
after the pathological failure of protein degradation. 
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Figure 7. A) Schematic representation of the normal nigrostriatal pathway (in red). SNc 
neurons project (thick solid red lines) to the basal ganglia and synapse in the striatum. B) In PD, 
the nigrostriatal pathway degenerates: there is a marked loss of DA neurons that project to the 
putamen (dashed line) and a much more modest loss of those that project to the caudate (thin 
red solid line) C) Immunohistochemical staining of Lewy Bodies found in DA neurons of PD 
patients in substantia nigra pars compacta. Unsoluble fibrous component of aggregates are 
detected with anti α-synuclein antibody and anti-ubiquitin (Dauer and Przedborski, 2003). 
 
 
3) Iron accumulation 
Iron is important for many biological processes. It is coordinated by heme, and it 
is an essential component of cytochromes as well as a cofactor of many different 
enzymes involved in the normal function of neuronal tissue. For example, 
tyrosine hydroxylase, which is required for dopamine synthesis, is a non-heme 
iron enzyme. 
Large amounts of iron are sequestered in neuromelanin granules in the DA 
neurons of the substantia nigra and the noradrenergic neurons of the locus 
ceruleus. Neuromelanin is synthesized by the oxidation of excess cytosolic 
catecholamines that are not accumulated in synaptic vesicles by vesicular 
monoamine transporter-2 (VMAT2). Interestingly, it binds iron avidly. 
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Iron accumulation in substantia nigra and globus pallidus has been also 
described as pathological hallmark of PD. The role of iron in neurodegenerative 
diseases, particularly PD, has not been clarified yet but different evidences show 
how its role, in combination with aging, could be critical for neurodegeneration 
of DA cells. To underline the toxic effect of iron in PD pathology it is important 
to mention that iron chelators, when administered prior to the exogenous toxin 
mimicking PD pathogenesis, appear neuroprotective in mice and non-human 
primates (Kaur et al., 2003). 
 
 
PD etiology 
PD is a multifactorial disease caused by both environmental and genetic factors. The 
cause of sporadic PD is unknown, but the environmental hypothesis was dominant 
for much of the 20th century for the discovery that an exogenous toxin can mimic the 
clinical and pathological features of PD. In 1983 Langston et al. discovered that 
people intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrydine (MPTP) 
developed a syndrome nearly identical to PD (Langston et al., 1983). Moreover, 
human epidemiological studies have correlated residence in rural environment and 
related exposure to herbicide (i.e. Paraquat) (Tanner, 1989) and pesticides (i.e. 
Rotenone) (Betarbet et al., 2000) with an elevated risk for PD. 
Although PD was long considered a non-genetic disorder of sporadic origin, 5–10% 
of patients are now known to have monogenic forms of the disease.  
The discovery of the genes involved and of their pathological mutations led to a 
better understanding of the mechanisms underlying this complex disorder. 
Clinical genetic testing can be helpful only for a limited number of cases with typical 
PD. However in atypical parkinsonian syndromes it could reveal mutations that are 
usually associated with other inherited diseases such as the spinocerebellar ataxias or 
the frontotemporal dementia (Gasser, 2015). 
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Table 1. Monogenic forms of PD (Gasser, 2015).  
 
 
PD pathogenesis 
Whatever the initial insult is, the analysis of human post mortem brains of PD 
patients as well as studies on PD animal models (neurotoxin-treated or genetic-
modified) suggest the involvement of two major, possibly interconnected, pathways 
in dopaminergic neurodegeneration: 
1) Protein misfolding and aggregation 
Alteration of protein folding, ubiquitin proteasome system (UPS) and autophagy 
are considered among the main molecular mechanisms in aggregate formation. 
The most important proteins involved in the correct folding of polypeptides are 
chaperons: this highly conserved class of proteins prevents inappropriate 
interactions within and between non-native polypeptides, enhances the efficiency 
of de novo protein folding and promote the refolding of stress-induced misfolded 
proteins (Hartl and Hayer-Hartl, 2002). When misfolded proteins cannot be 
“repaired” by chaperons, they have to be degraded. In the classical mechanism of 
degradation, proteins are poly-ubiquitinated to be degraded by the proteasome. 
Ubiquitination of a substrate requires a cascade of enzymes: ubiquitin-activating 
enzyme (E1), ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases 
(E3s) that are responsible for highly specific target recognition in this system 
through physical interactions with the substrate.  
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A relatively new discovered mechanism through which proteins can be degraded 
is autophagy. Most long-lived proteins, cytoplasmic constituents, including 
organelles, are sequestered into double-membrane autophagosomes, which 
subsequently fuse with lysosomes where their contents are degraded thanks to 
proteolytic enzymes. 
2) Mitochondrial dysfunctions: oxidative stress and alterated fusion/fission 
machinery 
A consequence of the mitochondrial dysfunction is oxidative stress and vice 
versa. Ninety-five percent of the molecular oxygen is metabolized within the 
mitochondria by the electron-transport chain: thus, mitochondria are highly 
exposed and damaged by oxidative stress. This leads to a more intense and 
perpetuating cycle in which reactive oxygen species (ROS) are generated. 
ROS cause functional alterations in proteins, lipids and DNA. Lipid damage 
leads to loss of membrane integrity and ions permeability, promoting 
excitotoxicity (Halliwell, 1992). Although ROS levels cannot be directly 
measured, the assessment of their reaction products and of the resulting damage 
in post mortem tissues is as an indirect index of their levels (Foley and Riederer, 
2000). 
Over the last several decades, evidence has accumulated that mitochondrial 
dysfunction is associated with PD. A mild deficiency in mitochondrial 
respiratory electron transport chain NADH dehydrogenase activity (Complex I) 
was first found in the substantia nigra of patients with PD (Mann et al., 1994; 
Schapira et al., 1989), followed by studies identifying a similar Complex I deficit 
in platelets (Blandini et al., 1998; Haas et al., 1995; Krige et al., 1992), 
lymphocytes (Barroso et al., 1993; Yoshino et al., 1992), and, less consistently, 
in muscle tissue (Penn et al., 1995; Taylor et al., 1994). The hypothesis that 
oxidative stress plays a role in the pathogenesis of PD was also previously 
proposed by the discovery that MPTP blocks the mitochondrial electron transport 
chain by inhibiting complex I (Nicklas et al., 1987). MPTP is highly lipophilic, 
and it crosses the blood-brain barrier within minutes. Once in the brain, it is 
oxidized to 1- methyl-4 phenyl-2,3-dihydropyridinium (MPDP+) by monoamine 
oxidase B (MAO B) in glial cells and serotoninergic neurons and then is 
spontaneously oxidized to MPP+. 
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Due to its high affinity for the DA transporter (DAT), it is selectively 
accumulated in DA neurons, where it causes toxicity and neuronal death through 
complex I inhibition. Similar toxic effects are produced by the common herbicide 
1,1’-dimethyl-4,4’-5 bipyridinium (Paraquat) coupled with the administration of 
the fungicide manganese ethylenepistithiocarbamate (Maneb). While Paraquat, 
which is structurally similar to MPTP, blocks the mitochondrial complex I, 
Maneb inhibits the mitochondrial complex III. Rotenone, that freely crosses 
cellular membranes and accumulates in subcellular organelles such as 
mitochondria, impairs oxidative phosphorylation by inhibiting complex I of the 
electron transport chain and leads to neuropathologic and behavioural changes in 
rats similar to human PD (Alam and Schmidt, 2002). Other important and 
complex processes involved in mitochondrial dysfunction are alteration in 
mitochondrial fusion and fission. Mitochondrial fission and fusion are important 
mechanisms that maintain the integrity of mitochondria, their electrical and 
biochemical connectivity, their turnover, and the segregation, stabilization, and 
protection of mitochondrial DNA (mtDNA). When altered, they cause 
morphological and functional mitochondrial abnormalities. The correlation 
between oxidative stress and fission/fusion machinery is still matter of debate but 
it seems that the presence of ROS can alter mitochondria morphology due to a 
disregulation of genes involved in this process like Mfn1, Fis1 and Drp1 (Liot et 
al., 2009; Zhang et al., 2011). These mechanisms are of high interest in neurons 
because these cells have unique features such as post-mitotic state and processes 
with higher energy requirements. Therefore, a fine regulation of dynamic fission 
and fusion processes are particularly important. In addition, mitochondrial 
fission/fusion machinery is intimately and critically involved in the formation of 
synapses and dendritic spines; preventing mitochondrial fission leads to a loss of 
mitochondria from dendritic spines and a reduction of synapse formation, 
whereas increasing fission increases synapse formation (Li et al., 2004). 
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Figure 8. A) Schematic representation of the MPTP metabolism and B) of MPP+ intracellular 
pathway (Dauer and Przedborski, 2003). 
 
 
In recent years the study of familial forms of PD proved the importance of 
mitochondria in the pathogenesis of the disease. Initial studies were concentrated 
on the high level of oxidative stress in the DA neurons of SN and on proteins 
such as DJ-1 (PARK7) contributing to the elimination of ROS (Clements et al., 
2006; Taira et al., 2004). Recently, the analysis focused on the mechanisms of 
fusion and fission that, if altered, lead to oxidative stress. In particular, genes 
such as DJ-1, Parkin (PARK2) and PINK1 (PARK6) are involved in controlling 
mitochondrial morphology by regulating fusion and fission (Dodson and Guo, 
2007). Finally, it is important to add that, although the molecular mechanisms are 
independent, the cellular pathways that control protein folding, protein 
A 
B 
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degradation and mitochondrial function are closely related and genes mutated in 
PD have been linked to several of these signalling pathways. 
 
 
Figure 9. Mechanism of neurodegeneration: linking oxidative stress and mitochondrial damage 
to UPS impairment and aggregates formation (Dauer and Przedborski, 2003). 
 
 
PD diagnosis 
PD diagnosis, at the early stages of the disease, is nowadays particularly difficult 
because it is mainly based on motor symptoms and on patient’s neurological history. 
The Society Brain Bank criteria are used in the clinic and they are subdivided in 
three steps here described. These criteria have an expected accuracy of up to 90% 
(Hughes et al., 2001). -­‐ Step 1. Diagnosis of Parkinsoniam Syndrome: bradykinesia and at least one 
among muscular rigidity, 4-6 Hz rest tremor, postural instability. -­‐ Step 2. Exclusion criteria for PD-like history of repeated strokes with 
stepwise progression of parkinsonian features, history of repeated head 
injury, history of definite encephalitis, oculogyric crises, neuroleptic 
treatment at onset of symptoms, more than one affected relative, sustained 
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remission, strictly unilateral features after 3 years, supranuclear gaze palsy, 
cerebellar signs, early severe autonomic involvement, early severe dementia 
with disturbances of memory, language, and praxis, Babinski sign, presence 
of cerebral tumor or communication hydrocephalus on imaging study, 
negative response to large doses of levodopa in absence of malabsorption, 
MPTP exposure. -­‐ Step 3. Supportive prospective positive criteria for PD. Three or more 
required for diagnosis of definite PD in combination with step one: unilateral 
onset, rest tremor present, progressive disorder, persistent asymmetry 
affecting side of onset most, excellent response (70-100%) to levodopa, 
severe levodopa-induced chorea, levodopa response for 5 years or more, 
clinical course of ten years or more. 
No standard tests are available nowadays to diagnose PD. Although the motor 
criteria together with the presence of neuronal loss in the SNc and of Lewy bodies in 
the surviving neurons are established as hallmarks of the pathology, the International 
Parkinson and Movement Disorder Society has pointed the needs of new criteria 
(Berg et al., 2013). By the time motor symptoms appear, PD patients have already 
lost 60-70% of the DA-producing cells in the SNc (Dauer and Przedborski, 2003) 
and therefore in most cases the disease is diagnosed many years after the onset. The 
pharmacological treatment can be more effective if patients can benefit from it in the 
premotor phase. 
It is therefore imperative to identify peripheral biomarkers of PD. A biomarker is 
defined as “a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes or pharmacological responses 
to a therapeutic intervention” (from National Institutes of Health Biomarkers 
Definitions Working Group). 
To this purpose, many efforts have been made to find a “PD signature” using 
different approaches that are summarized in Figure 10. Some biomarkers should 
predict if a patient is responding well to therapy, helping to monitor the disease 
progression in an objective way and providing a “personalized medicine” taking 
advantage of different approaches. 
Clinical standard methods can measure olfactory impairment (for example with the 
University of Pennsylvania’s smell identification test) and the rapid eye movement 
sleep behaviour disorder (with polysomnography). 
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Imaging technologies like positron emission tomography (PET) and single photon 
emission computed tomography (SPECT) could be helpful to measure SNc DA 
neuronal loss however they cannot distinguish PD from other diseases with SNc 
degeneration. Furthermore, PET and SPECT imaging are abnormal only when a 
significant loss has been reached. 
Cardiac scintigraphy could be helpful to differentiate PD from multiple system 
atrophy (MSA), which often presents with some of the same symptoms, 
demonstrating that in PD with autonomic failure, but not in MSA, there is a 
myocardial postganglionic sympathetic dysfunction (Courbon et al., 2003). 
Pathological approaches include colonic biopsy and skin biopsy both with α-
synuclein staining that has been demonstrated to accumulate within the enteric 
peripheral nervous system (Visanji et al., 2014) and in the skin (Donadio et al., 2014) 
of PD patients. 
Biochemical assays on biological fluids represent a relative non-invasive promising 
test although good candidates are still needed. 
Finally, the genetic approach can be useful in patients with family members with a 
known monogenic form of PD. 
A single methodology should not be exhaustive for the diagnosis and therefore a 
combination of these technologies might be required (Kalia and Lang, 2015). 
 
 
Figure 10. Potential biomarkers for diagnosis of PD. Many potential PD biomarkers are 
currently under investigation and they can be divided into clinical, imaging, pathological, 
biochemical and genetic. For an accurate diagnosis a combination of biomarkers is essential. 
DTBZ=dihydrotetrabenazine; CSF=cerebrospinal fluid; DTI=diffusion tensor imaging; 
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CIT=2β-carbomethoxy-3β-(4-iodophenyl)tropane; MIBG=metaiodobenzylguanidine; 
MLPA=multiplex ligation-dependent probe amplification; MW=molecular weight; 
PET=positron emission tomography; RBD=rapid eye movement sleep behaviour disorder; 
SPECT=single photon emission computed tomography; UPSIT=University of Pennsylvania’s 
smell identification test (Kalia and Lang, 2015). 
 
 
Blood Transcriptomics in PD 
A blood test to diagnose PD would be ideal because blood is an easily accessible 
tissue.  
Gene expression analysis is a powerful tool to study complex disorders such PD and 
it has been used to find biomarkers (Papapetropoulos et al., 2007). Given the 
systemic nature of the disease, it is not surprising that many works described 
alterations of blood physiology in PD patients, such as upregulation of α-synuclein at 
mRNA and protein levels (Kim et al., 2004), alteration in coenzyme Q10 (CoQ10) 
redox state (Shults and Haas, 2005), increased monoamine oxidase (MAO) 
molecular activity (Bongioanni et al., 1996), cytogenetic alterations in blood 
lymphocytes (Migliore et al., 2002; Petrozzi et al., 2002), decreased phagocytic 
function of blood polymorphonuclears (Salman et al., 1999), lowered levels of 
glutathione (Larumbe Ilundáin et al., 2001), higher levels of interleukin 1 beta 
(Bessler et al., 1999). 
A short but significant list of recent microarray-based studies has used human blood 
as RNA source to look for differentially expressed genes in sporadic and genetic PD 
patients (Karlsson et al., 2013; Kedmi et al., 2011; Mutez et al., 2011, 2014; 
Potashkin et al., 2012; Scherzer et al., 2007; Soreq et al., 2008). In the pioneering 
work by Scherzer et al., 22 genes were identified with microarray profiling of whole 
blood of 50 PD patients, among which 9 de novo subjects. A risk marker given by 8 
genes (VDR, HIP2, CLTB, FPRL2, CA12, CEACAM4, ACRV1, and UTX) 
predicted PD and was not biased by dopamine replacement therapy. The analysis of a 
genetically homogenous population of 88 Ashkenazi patients (Kedmi et al., 2011), 
including 20 de novo, evidenced for the first time the decreased expression of B 
cells-related genes in PD. Karlsson et al. analyzed samples from 79 PD subjects at 
different stages of the disease, including 23 de novo patients and relative controls, 
proposing a classifier predicting sporadic and de novo PD. LRPPRC, BCL2 and 
SRSF8 were shared with the 22 genes list as in Scherzer et al. Furthermore, it 
presented HSPA8 and UBE2K/HIP2 in common with Molochnikov et al., 2012. 
Introduction	  
	   29	  
Potashkin et al. took advantage of splice variant-specific microarrays to identify a 
biosignature composed of 13 mRNAs (c5orf4, wls, macf1, prg3, eftud2, pkm2, 
slc14a1-s, slc14a1-l, mpp1, copz1, znf160, map4k1 and znf134) whose expression is 
altered in peripheral blood of early-stage PD patients. Recently, they identified two 
novel longitudinally markers (HNF4 and PTB1) by means of network-based and 
transcriptomic meta-analyses (Santiago and Potashkin, 2015). Interestingly, gene 
expression analysis of peripheral blood mononuclear cells from 20 sporadic PD 
patients and 9 individuals, heterozygous for the LRRK2 G2019S mutation, showed 
deregulation of the immune system, endocytosis and eukaryotic initiation factor 2 
signaling (Mutez et al., 2014). 
Although there are a number of promising gene signatures, blood transcriptomics 
have not yet delivered the expected results for biomarker discovery in PD. One of the 
major concerns is the scarce overlap among candidate genes’ lists of these studies. 
Variances in the procedures for collection, processing and analysis of samples may 
strongly limit the reproducibility of gene expression data. Importantly, these 
differences may also be explained in biological terms. First, genetic variations in 
human populations may lead to diversity in transcriptional changes in disease. 
Furthermore, the majority of these works analyzed peripheral blood samples from 
sporadic PD patients at different stages of the disease and under pharmacotherapy 
raising the questions of whether changes are related to the disease stage, therapy or 
both. Finally, it is now clear that PD is a systemic and a highly heterogeneous 
disease, as classified according to distinct clinical subtypes (Thenganatt and 
Jankovic, 2014). 
On the other hand, blood transcriptomics studies identify a common repertory of 
enriched GO biological terms as altered in PD. These include “neuronal apoptosis”, 
“mitochondrial dysfunction”, “leukocyte activation” and “deregulation of the 
immune system”.  
 
 
Nitrogen permease regulator-like 3 (Nprl3)  
Nitrogen Permease Regulator-Like 3 (Nprl3) gene was discovered in 1995 by the 
group of Higgs who described its position and sequence. It lies on the telomeric 
region of human chromosome 11 and contains in its intron the major regulator 
elements of α globin, which cluster is adjacent (Vyas et al., 1995). 
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The same group studied the sequence homologies by comparative analysis between 
human, mouse, chicken, and zebrafish revealing a syntenic region that includes the 
whole cluster of α-globin genes and the extended 5′-terminal region where Nprl3 
gene is located (Flint et al., 2001; Tufarelli et al., 2004). It is transcribed in the 
direction opposite to the direction of the globin gene transcription and for many 
years was represented in different database under the name of C16orf35. Neklesa & 
Davis in 2009 changed its name in Nprl3 discovering the homology with Nitrogen 
Permease Regulator 3 (Npr3) yeast protein (Neklesa and Davis, 2009). 
Vyas et al. 1995 reported the characterization of Nprl3 gene adjacent to the alpha 
globin cluster on chromosome 16p13.3, containing 15 exons and spanning about 55 
kb. Its sequence and position has been conserved for at least 270 million years. 
To date 5 different Nprl3 isoforms are annotated in the databases and their main 
differences are in the 5’ region (5’UTR and position of the translational starting 
codon). 
 
 
Figure 11. Schematic representation of Nprl3 gene isoforms. Transcription direction is from 
right to left since the gene is on the (-) strand of DNA. 
 
 
Nprl3 expression regulation has been not yet extensively studied, however, the 
isoform 1 is considered as the canonical one. Therefore, in this thesis, when the 
isoform is not specified, “Nprl3” refers to isoform 1. 
Nprl3 expression is ubiquitous and it has been found upregulated in human and 
mouse erythroid cells, where high level of α-globin expression occurs (Kowalczyk et 
al., 2012; Lower et al., 2009).  
The mammalian alpha globin locus lies within a region of 135–155 kb of conserved 
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synteny, and human gene arrangement is 5′-ζ-αD-α2-α1-θ-3′, where α1 and α2 are 
hemoglobin alpha genes, ζ gene encoder for an alpha-like protein expressed during 
embryonic development, θ and αD are two pseudogenes (Figure 12) (Vernimmen, 
2014). 
Interestingly, Nprl3 gene is fundamental for hemoglobin alpha (HBA) genes 
expression: the evolutionarily conserved remote elements which regulate their 
expression correspond to erythroid-specific DNase1 hypersensitive sites located 40-
60 kb upstream of the α genes (Hughes et al., 2005). These elements are called 
erythroid-specific multispecies conserved sequences (MCS) and they are numbered 
MCS-R1 to MCS-R4. Three of these elements (MCS-R1, MCS-R2, and MCS-R3) 
are located in Nprl3 introns and MCS-R4 lies upstream of the promoter of that gene 
(Vernimmen, 2014). 
MCS-R2 (called also HS-40) lies in the fifth intron of Nprl3 gene and its deletion 
leads to almost complete down-regulation of alpha-gene expression causing severe 
thalassemia (Bernet et al., 1995).  
Quantitative chromosome conformation capture analysis performed by Vernimmen 
and colleagues in 2007 demonstrated that a looped structure that bridges the remote 
regulatory elements to the promoter is involved in this distal regulation. This 
regulatory sequence does not influence expression of Nprl3 gene, which has a GC-
rich promoter (unlike the TATA-type promoters of the alpha globin loci) 
(Vernimmen et al., 2007).  
 
 
 
Figure 12. The chromosomal organization of human alpha-globin locus. Nprl3 gene lies 
upstream to the alpha-globin genes and pseudogenes (ζ, αD, α2, α1, θ) on the opposite strand of 
DNA. It contains the major regulators of alpha-globin expression that are indicated as R1-R4 
multispecies conserved sequences (MCS) that correspond to DNA hypersensitive sites (HSs) 
(Vernimmen, 2014). 
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Nprl3 protein 
Although Nprl3 gene discovery dates back to 1990s, for many years the deduced 
protein has not been studied even if it is highly conserved in metazoa, suggesting a 
conserved function. 
Lunardi et al., 2009 demonstrated that Nprl3 encodes for a 64 kDa nucleo-
cytoplasmic protein. By overexpressing it, they noticed that nuclear Nprl3 may be 
localized into the PML nuclear bodies, the matrix-associated domains that are 
proposed to recruit many proteins and regulate different nuclear functions such as 
DNA replication, transcription or epigenetic silencing (Stuurman et al., 1990). 
They showed that Nprl3 overexpression inhibits cell proliferation in a human 
osteosarcoma cell line and that Nprl3 protein could bind all p53-family proteins, with 
a higher affinity for p73. Indeed the interaction with these transcription factors may 
suggest a role of Nprl3 in cell cycle control, tumor suppression and development. 
When Neklesa & Davis screened the yeast genome, searching for genes responsible 
of amino acid sensing and starvation, they discovered that the evolutionary 
conserved Npr2/Npr3 complex is responsible of TORC1 activity in response to 
amino acid deprivation. Furthermore, they suggest their function is conserved since 
they proved Nprl2/Nprl3 interaction in mammals (Neklesa and Davis, 2009). 
In 2013, Levine et al. identified two functional domains in Nprl2 and Nprl3 proteins: 
a longin domain (LD) at the N-terminal and two or more helix turn helix (HTH) 
domains at the C-terminal. The latter might bind DNA, RNA or protein partners. The 
first one comprises a five-stranded β-sheet core sandwiched between an α-helix on 
one side and two α-helices on the other. LDs have been found in many GDP/GTP 
exchange factors (GEF) that activate Rab-GTPases (Levine et al., 2013). The authors 
suggest that LDs could act as a platform for a GTPase involved in TORC1 
signalling. 
Notably, studying the genetic determinants of haemolysis in sickle cell anemia 
Milton et al. found an association between a SNP in NPRL3 first intron (rs7203560) 
and haemolytic score. They showed that SNPs close to MCS are in strong linkage 
disequilibrium (LD) with rs7203560: they hypothesized that this could be a marker 
for one or more variants in or near MCS that downregulate α-globin expression 
causing a mild thalassemia-like effect (Milton et al., 2013). 
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Figure 13. Levine et al. model for Nprl2/Nprl3 interaction. The longin domains (LDs) at their N-
terminal (light blue) could form a platform for a small GTPase unknown (red), whereas the 
helix turn helix (HTH) domains at their C-terminal (orange) might bind DNA, RNA or proteins 
(Levine et al., 2013). 
 
 
Mammalian Target of Rapamycin (mTOR) 
TOR protein is the target of Rapamycin, a drug produced by Streptomyces 
Hygroscopicus bacteria and discovered in the 1970s (Vézina et al., 1975). The 
remarkable effect of this drug was its strong antiproliferative property and in the 
1990s its cellular target was determined in yeast and named TOR (Cafferkey et al., 
1993; Kunz et al., 1993). The mammalian homologous was then found and named 
mTOR (Brown et al., 1994; Sabatini et al., 1994; Sabers et al., 1995). 
mTOR is a 289 kDa serine/threonine kinase that belongs to the phospho-inositide 3-
kinase (PI3K)-related kinase family. It forms 2 protein complexes with different 
interactors, and each complex, called mTORC1 and mTORC2, has different 
Rapamycin sensitivity and different upstream inputs and downstream effectors. 
mTORC1 and mTORC2 are two large protein complexes that in addition to the 
catalytic subunit have respectively five and six interacting components. These are: 
regulatory-associated protein of mTOR (Raptor); mammalian lethal with Sec13 
protein 8 (mLST8); proline-rich AKT substrate 40 kDa (PRAS40); and DEP-
domain-containing mTOR-interacting protein (Deptor). 
The other components of mTORC2 are: rapamycin-insensitive companion of mTOR 
(Rictor); mammalian stress-activated protein kinase interacting protein (mSIN1); 
protein observed with Rictor-1 (Protor-1); mLST8; and Deptor (Laplante and 
Sabatini, 2009). 
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Figure 14. The two mTOR protein complexes regulate different pathways and have distinct 
upstream regulators. mTORC1 responds to oxygen, amino acids, stress, energy levels, growth 
factors and it is sensitive to acute treatments with Rapamycin. It promotes cell growth by 
regulating metabolism and promotes cell cycle progression. mTORC2 is sensitive to chronic 
Rapamycin but not to acute treatment. It regulates cell survival, metabolism and cytoskeletal 
organization (adapted from Laplante and Sabatini, 2012). 
 
 
Up to now, mTORC1 pathway has been better characterized than mTORC2. It 
regulates cell growth integrating different inputs like growth factors, stress, energy 
status, oxygen, and amino acids and controls fundamental cellular pathways 
including protein and lipid synthesis and autophagy. 
Amino acid sensing by mTORC1 initiates within the lysosomal lumen inducing its 
translocation to the lysosomal surface, where it becomes active. This activation 
requires a signalling machine associated with the lysosomal membrane that consists 
of the Rag GTPases, the Ragulator complex, and the vacuolar ATPase (v-ATPase) 
(Bar-Peled et al., 2013).  
 
 
Nprl3 takes part of a protein complex that inhibits mTORC1 
An important contribution to understand mTORC1 regulation was provided by the 
work of Neklesa and Davis, 2009 (in yeast) and Bar-Peled et al., 2013 (in mammals). 
In these papers, Nprl3 protein was proved to be part of a protein complex that 
inhibits mTORC1 activity.  
In details, Bar-Peled et al. identified GATOR as a complex interacting with Rag 
GTPases present on lysosomal surface and composed of two subcomplexes called 
GATOR1 and 2. 
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Inhibition of GATOR1 subunits (DEPDC5, Nprl2, and Nprl3) makes mTORC1 
signalling resistant to amino acid deprivation, whereas inhibition of GATOR2 
subunits (Mios, WDR24, WDR59, Seh1L, Sec13) suppresses mTORC1 signaling. 
Epistasis analysis showed that GATOR2 negatively regulates DEPDC5. 
GATOR1 is considered a tumor suppressor since mutations of its components are 
associated to hyperactive mTORC1 and therefore to a cancer phenotype: in fact, loss 
of DEPDC5 and Nprl2 genes was observed in human glioblastoma and ovarian 
cancer tissues (Bar-Peled et al., 2013). 
Nprl3 ablation was studied by Kowalczyk et al., 2012 taking advantage of a mouse 
model in which the constitutive promoter of Nprl3 has been removed. They showed 
that the mice die during late gestation with cardiovascular system defects and the 
main expression alterations have been found in protein synthesis and cell cycle 
genes, because of mTOR pathway perturbation. 
Phenotypically mice showed severe myocardium abnormalities suggesting that Nprl3 
is a candidate gene for harbouring mutations in individuals with similar pathological 
symptoms (Kowalczyk et al., 2012). 
 
 
Figure 15. The GATOR complexes and their role in mTORC1 regulation. GATOR2 inhibits 
GATOR1 that in turn inhibits Rag GTPase A (RagA) activation. Ragulator complex has an 
opposite effect because it stimulates GTP loading on RagA, which activates mTORC1 in 
response to amino acid availability (Shaw, 2013). 
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mTORC1 and human diseases 
In eukaryotes TOR is the major sensor of nutrients, energy and stress. Therefore, it is 
not surprising that alterations in its pathway have been correlated with diseases and 
conditions where growth and homeostasis are compromised like cancer, metabolic 
diseases and ageing. 
mTORC1 pathway alterations have many phenotypic consequences. First, mTORC1 
inhibition is correlated with increased lifespan (Bjedov et al., 2010; Hansen et al., 
2008). mTORC1 pathway inactivation also counters aging and mitigate age-related 
diseases including neurodegenerative diseases (Johnson et al., 2013).  
In this context, the mTORC1 inhibitor Rapamycin decreases the formation of toxic 
huntingtin aggregates in fly and mouse model of Huntington’s Disease (Ravikumar 
et al., 2004), prevent the synthesis and aggregation of tau protein in Alzheimer’s 
Disease in vitro models (Tang et al., 2013) and confers neuroprotection from PD 
toxins both in vitro and in vivo  (Malagelada et al., 2010). 
Many findings support the importance of mTOR in cancer pathogenesis. Several 
human cancers harbour mutations in the PI3K signalling pathway components, 
which is upstream both to mTORC1 and mTORC2. p53 loss, a common feature in 
cancer, promotes mTOR. Other tumor suppressors like Tsc1/2, serine threonine 
kinase 11 (Lkb1), Pten, and neurofibromatosis type 1 (Nf1) are associated with 
mTOR upstream regulation that is fundamental for cancer growth, survival and 
proliferation (Laplante and Sabatini, 2012). Figure 16 shows the downstream effects 
of mTOR stimulation in cancer. 
 
Figure 16. mTOR signalling in cancer. Tumorigenesis is promoted upon mTOR stimulation: 
oncogenes are in red and tumor suppressor in green. The asterisk indicates proteins currently 
targeted for cancer therapy (adapted from Laplante and Sabatini, 2012). 
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Since it responds to nutrients and growth factor levels, mTOR signalling has been 
also associated to metabolic diseases such as obesity, non-alcoholic fatty liver 
disease, insulin resistance and type 2 diabetes (Laplante and Sabatini, 2012). 
In the blood, mTORC1 has been correlated with erythropoiesis, anemia and 
methionine homeostasis. 
Knight et al., 2014 found high levels of phosphorylated ribosomal protein S6 in 
mouse blood reticulocytes, as a consequence of a high mTORC1 activity. They 
raised the hypothesis that mTORC1 can be regulated by iron availability, as shown 
by Ohyashiki et al., 2009, and could modulate iron metabolism, as demonstrated by 
Bayeva et al., 2012 and La et al., 2013. In fact, they detected a marked reduction in 
mTORC1 signalling in the red blood cells (RBCs) of mice in response to iron-
deficient diet. 
Furthermore, they demonstrated that in RBCs, mTORC1 activation induces 
macrocytic anemia (RBC size increase, increased hemoglobin, lower RBC number 
and lower hematocrit). On the contrary, genetic mTORC1 ablation induces 
hypochromic microcytic anemia and perinatal lethality. 
Finally, in the adult mice, mTOR inhibition strongly impairs erythropoiesis 
influencing the growth and proliferation of erythroid progenitors (Knight et al., 
2014). 
Interestingly, some types of hereditary anemias can be ameliorated by 
pharmacological activation of mTORC1 (Jaako et al., 2012; Payne et al., 2012). 
Consistent with these findings, Dutchak et al., 2015 showed that the GATOR1 
component Nprl2 is required for mouse viability and that its absence significantly 
compromises hematopoiesis. 
Furthermore, they demonstrated that Nprl2 regulates the uptake and availability of 
cobalamin (vitamin B12), which in turn is required for methionine and S-Adenosyl 
methionin (SAM) synthesis that are part of important metabolic pathways for 
hematopoiesis (Klee, 2000; Koury and Ponka, 2004). 
Recently, Sim and colleagues (2015) identified Nprl3 gene mutations and subsequent 
mTOR activation in patients with familial focal cortical dysplasia (FCD). 
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Rapamycin effects on PD 
Besides the importance of mTORC1 in homeostasis maintenance and the 
perturbation of its pathway upon disease, many works have studied the therapeutic 
effects of mTORC1 inhibitor Rapamycin in PD. 
Two works published in 2010 show that this drug reduces dopaminergic nigrostriatal 
degeneration in the MPTP model of PD. They hypothesize two different mechanisms 
of neuroprotection: Malagelada et al. proposed that Rapamycin blocks translation of 
the pro-cell death protein RTP801, which is induced in affected neurons of PD 
patients and causes neuronal cell death by suppressing activation of mTOR 
(Malagelada et al., 2010). On the other hand, Dehay et al. proposed that the effect is 
driven by induction of lysosome-mediated autophagic degradation (Dehay et al., 
2010). In particular, Rapamycin triggers lysosomal biogenesis, stimulates 
autophagosome-lysosome fusion and enhances lysosome-mediated clearance of 
accumulated autophagosomes. 
Autophagic stimulation may also enhance neuronal survival by decreasing apoptosis: 
in PD models autophagy is impaired, leading to dysfunctional mitochondria 
accumulation and release of mitochondrial pro-apoptotic factors, such as cytochrome 
c (Bové et al., 2011). Moreover, the ubiquitine-proteasome system, altered in PD, 
may be affected by Rapamycin treatment (Dauer and Przedborski, 2003). 
Finally, working on a mouse model, Santini and colleagues showed that levodopa 
stimulates mTORC1 and this sustained activity induces dyskinesia, a typical side 
effect that appears in PD patients medicated with levodopa. The inhibition of 
mTORC1 upon Rapamycin administration could ameliorate this side-effect without 
affecting levodopa benefits (Santini et al., 2009). 
Therefore, the mechanism of neuroprotection exerted by Rapamycin seems to 
involve various molecular pathways and it is likely that all contribute to the 
neuroprotective effect on PD (Bové et al., 2011). 
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Preliminary data 
As shown in Calligaris et al. (BMC Genomics; in press), the laboratory of Prof. 
Gustincich aimed to identify gene expression patterns in peripheral blood of de novo 
and drug-naïve PD patients by comparing 40 sporadic PD versus 20 HCs 
(“Discovery set”). To this purpose, patients were enrolled at the early clinical stage 
of the disease as evaluated by a neurologist. Subjects did not take any centrally 
acting drugs in the previous 6 months. Most patients showed a prevalent asymmetric 
parkinsonian symptomatology that, in the majority of cases, comprised the classical 
triad of tremor, bradykinesia, and rigidity. Accordingly, an asymmetric reduction of 
striatal activity on the 123I-FP-CIT SPECT images was observed. The prevalent case 
consisted of a putaminal alteration contralateral to the clinical most affected side.  
Blood was collected from study subjects into PAXgene Blood RNA tubes 
(PreAnalytiX, Hombrechtikon, CH) after a fasting period and at the same time of the 
day to limit circadian-dependent variability. Hybridization targets were synthesized 
with OvationTM Whole Blood Solution (NuGEN) and hybridized to HG−U133A 2.0 
arrays (Affymetrix, Santa Clara, CA), investigating the expression of 18400 
transcripts.  
By applying Ranking-Principal Component Analysis, PUMA and Significance 
Analysis of Microarrays, gene expression profiling discriminated patients from HC 
and identified a common repertory of 54 genes as differentially expressed in blood. 
The majority of these were also present in DA neurons of the substantia nigra, the 
key site of neurodegeneration. Together with neuronal apoptosis, lymphocyte 
activation and mitochondrial dysfunction, already found in previous analysis of PD 
blood and post-mortem brains, they unveiled transcriptome changes enriched in 
biological terms related to epigenetic modifications including chromatin remodeling 
and methylation. Candidate transcripts were validated by RT-qPCR in an 
independent cohort of 12 patients and controls (“Validation set”). 
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Aim of this work 
In this work we took advantage of nanoCAGE technology to find alterations in the 
blood transcriptome of 20 drug naïve de novo PD patients and 20 HC. 
The most up-regulated nanoCAGE tag is located in the third intron of the gene 
Nitrogen Permease Regulator Like Protein 3 (Nprl3). 
The aim of my PhD thesis was to identify the full-length transcript associated to the 
nanoCAGE tag, validate it, and to test whether it may represent a peripheral 
biomarker of PD. 
Here I show that the tag represents an alternative Transcription Start Site of Nprl3 
(TagNprl3). It is associated to a TCT motif (YC+1TYTYY) for initiation of 
transcription, which has been found to be specific for ribosomal protein-coding genes 
and those involved in protein synthesis. The tag maps to a 29nt minisatellite that is 
found repeated 16 times in the reference genome. High tag expression is associated 
to an allelic variant of 13 repeats. To our knowledge, this is the first time that a 
minisatellite variant is both a TSS and an eQTL.  
Unfortunately, high TagNprl3 expression resulted not to be correlated to PD but to 
heterozygosity. Furthermore, allelic frequencies were not correlated to PD.  
We then showed that TagNprl3 is expressed in RBCs both at mRNA and protein 
levels giving rise to an isoform truncated at the N-terminal. This is able to interact 
with its protein partner Nprl2 and its overexpression inhibits cell proliferation.  
This work provides hints for Nprl3 protein function in blood and may suggest a 
testable hypothesis linking mTOR activity to genomic polymorphisms in modifier 
genes.  
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Materials and methods 
 
 
Blood collection and RNA purification 
The study was approved by the local institutional Ethical Committee at the 
Movement Disorders Center of the Neurologic Clinic of Trieste (Italy). Study 
participants gave written informed consent. We enrolled 20 patients with a first 
clinical diagnosis of PD, according to the UK Parkinson’s Disease Society Brain 
Bank criteria. Twenty healthy age- and ethnicity-matched control subjects (HC) 
travelling with the patients were also included in the study.  
Blood was collected from study subjects after a fasting period. Samples were 
harvested directly and sequentially into 8 PAXgene Blood RNA tubes (PreAnalytiX, 
Hombrechtikon, CH) via a 21−gauge butterfly needle and then frozen and kept at -
80°C. Total RNA was purified using PAXgeneTM Blood RNA kit (PreAnalytiX 
GmbH, Qiagen, Hilden, Germany) and DNaseI treatment was performed by ‘on-
column’ treatment as recommended by manufacturer’s instructions plus a second 
treatment subsequent to elution. RNA was then purified using RNase column 
(Qiagen, Hilden, Germany) and quantified by Nanodrop ND-100 Spectophotometer 
(NanoDrop Technologies; Wilmington, DE). RNA integrity was determined with 
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) and exclusively samples 
with RIN ≥ 8 were included in the subsequent investigations.  
These steps were performed by Dr. Calligaris in the laboratory of Prof. Gustincich. 
 
 
Nano CAGE 
For a detailed description of nanoCAGE please refer to Plessy et al., 2010. This step 
was performed by Dr. Dave Tang in the laboratory of Prof. Carninci (Riken, Japan). 
 
 
Rapid amplification of cDNA ends (RACE) 
RACE technique allows the amplification of full-length 5′ and 3′ ends of cDNA 
starting from a known partial sequence obtained for example from library screening 
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such as nanoCAGE. 
RACE was performed using the GeneRacer cDNA amplification kit (Invitrogen). 
1 µg of total RNA has been retrotranscribed into cDNA modified with the 
GeneRacer 5’ and 3’ adaptors following the manufacturer’s protocol, using poly-T 
primer in the 20 µl reverse transcription reaction.  
All RACE reactions were performed by nested PCR. For the first amplification, 1 µl 
cDNA obtained from the retrotranscription reaction was used as a template together 
with GeneRacerTM 5′ Primer or the GeneRacerTM 3′ Primer, when performing 5’ or 
3’ RACE reactions, respectively, and gene-specific primers: REV_first_5RACE for 
5’RACE and FW_3RACE for 3’RACE (see Table 2). 
PCR was performed with Platinum Taq High Fidelity (Invitrogen) under the 
following conditions: 94°C for 2 min, followed by 5 cycles at 94°C for 30 s, 72°C 
for 1 min; 5 cycles at 94°C for 30s, 70°C for 1 min, 25 cycles at 94°C for 30s, 68°C 
for 30 s, 68°C for 1 min, and a final extension at 68°C for 10 min. 
1 µl of this PCR product was used as template for the nested PCR together with 
GeneRacerTM 5′ Nested Primer or the GeneRacerTM 3′ Nested Primer, when 
performing 5’ or 3’ reactions, respectively, and a second nested gene-specific 
primers: REV_nested_5RACE for 5’RACE and FW_3RACE (the same of the first 
reaction) for 3’RACE.  
Nested PCR was performed under the following conditions: 94°C for 2 min, 
followed by 40 cycles at 94°C for 30s, 65°C for 30 s, 68°C for 2 min, and a final 
extension at 68°C for 10 min. PCR products were resolved on 1% agarose gel. The 
amplicons were cloned in pGEM-T Easy vector (Promega) and sequenced at the 
Eurofins MWG Operon Inc. facility. 
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Primer Sequence (5’   3’) 
GeneRacerTM 5′ Primer CGACTGGAGCACGAGGACACTGA 
GeneRacerTM 3′ Primer GCTGTCAACGATACGCTACGTAACG 
GeneRacerTM 5′ Nested Primer GGACACTGACATGGACTGAAGGAGTA 
GeneRacerTM 3′ Nested Primer CGCTACGTAACGGCATGACAGTG 
REV_first_5RACE CCCAGAGCATGCTGTAGCAGTGTT 
FW_3RACE GAGTGTGTGATCCTGTTTCTCAGCGTG 
REV_nested_5RACE ATAACATCTGAAAACCAGACAAGAAACA 
   
Table 2. List of primers used in RACE assays. 
 
 
Identification of Minisatellite Polymorphism 
Genomic DNA has been extracted from blood samples taking advantage of QIAamp 
DNA Blood Mini Kit (Qiagen) following the manufacturer’s protocol (Dr. Calligaris, 
Dr. Vlachouli, Dr. Finaurini). 
PCRs were performed in 96 well plates, on a total of 20 ng/5 µl of human genomic 
DNA per well, by using ExTaq Takara on a total of 50 µl reaction volume, as 
specified by the manufacturer. Primers were used at a final concentration of 200 nM 
and are indicated on Table 3. 
The two primers were designed to map externally to the repeated region in order to 
obtain the amplification of the entire minisatellite. The cycling conditions were: 
94°C for 3 min, followed by 35 cycles at 94°C for 30 s, 62.4°C for 30 s, 72°C for 1 
min, and a final extension at 72°C for 5 min. Reaction products were visualized on a 
1.3% agarose gel. 
 
Primer Sequence (5’   3’) 
VNTR_FW GCAGAAGTGCCACCATTAAGCA 
VNTR_REV AAACCCCATGGTAAGCGTTGA 
 
Table 3. Primers used for minisatellite polymorphism identification. 
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Luciferase reporter assay 
This assay allows testing genomic sequences for their putative function in the 
regulation of gene expression. 
It gives a quantitative measurement of the level of expression of the luciferase 
reporter gene under the control of the genomic DNA sequence to be tested. 
Minisatellite alleles have been cloned into pTAL-Luc vector (Clontech) that is an 
enhancerless vector that express firefly Luciferase gene under the control of a 
minimal TATA-like promoter region from the Herpes simplex virus thymidine 
kinase (HSV-TK) promoter and it is ideal for the study of putative enhancer 
sequences. 
The inserts have been amplified with modified Table 3 primers, adding XhoI and 
KpnI restriction sites in order to obtain four different constructs, with the two 
minisatellite alleles in both orientation, since enhancer activity might be orientation-
dependent. 
 
 
Figure 17. Restriction map and multiple cloning site (MCS) of pTal-Luc.  
 
 
The assay was performed taking advantage of lymphoblastoid K562 cell line 
(chronic myelogenous leukemia) maintained in RPMI 1640 (GIBCO) supplemented 
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with 10% fetal bovine serum (SIGMA-ALDRICH), 1% GlutaMAX, 100 U/ml 
penicillin and 100µm/ml streptomycin (SIGMA) at 37°C in a humidified CO2 
incubator. 
K562 cells were transfected with Lipofectamine 2000 Transfection Reagent 
(Invitrogen) following manufacturer instructions. For each well the pTAL-Luc vector 
to be tested was transfected together with Tk-Ren normalization vector (Promega), 
that express renilla luciferase under the same TATA-like promoter, in a ratio 10:1. 
After 48 hours from transfection, the activities of firefly and renilla luciferase were 
measured using the Dual-Luciferase Assay Kit (Promega). 
Luciferase activity ratio (firefly/renilla) for each transfection condition was 
normalized to the ratio obtained with control plasmid (pTAL-Luc empty). 
Normalization to the mean activity of the control condition gave the fold-change in 
luciferase activity values presented. 
 
 
Genome wide association study (GWAS) 
We carried out a genome-wide association study (GWAS) to identify hypothetical 
variants associated to minisatellite polymorphism. 
The analysis was carried out by Prof. Pio D’Adamo (Consorzio per il Centro di 
Biomedicina Molecolare – CBM, Trieste) on the genomic DNA of PD and HC 
taking advantage of HumanOmniExpressExome BeadChip (Illumina) array. 
The array is designed to capture the greatest amount of common SNP variation. 
 
 
RT-PCR and Real-Time TaqMan PCR 
To validate the full-length TagNprl3 transcript, 1 µg of total RNA was reverse-
transcribed in a final volume of 20 µL using Superscript III Reverse Transcriptase 
(Invitrogen), 25 ng random hexamers and 2.5 µM oligo(dT) 20 primers according to 
the manufacturer’s recommendations. 
PCR mix was prepared by adding 1 µL of the so prepared cDNA to 5 units of 
TaKaRa Ex Taq, 10X Ex Taq Buffer, dNTP Mixture (200 µM final concentration 
each) (TaKaRa), 200 nM of primer FW_3RACE (see Table 2), 200 nM of primer 
REV (5’-CCTTTCCAAACCTGCGCACC-3’), and water to a final volume of 50 µL.  
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The FW_3RACE is the same forward primer used to amplify the full-length 
transcript in 3’RACE assay, while the REV primer was designed in the 3’UTR 
region of TagNprl3. The couple of primers used to amplify Nprl3 isoform 1 is 
indicated on Table 4. 
The PCR protocol is the following: 95°C for 5 min, followed by 40 cycles at 95°C 
for 15 s, 60°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 5 min. 
PCR products were resolved on 1% agarose gel. 
Real-Time PCR is a technique that allows determining the starting quantity of a 
template through amplification and detection of nucleic acids. It is an accurate, 
specific and high sensitive method that, by the use of fluorescent molecules, such as 
DNA-binding dyes or fluorescently labeled sequence-specific probes, detects the 
amplicon at each step of amplification. The introduction of TaqMan fluorescently 
labeled sequence-specific probes increases the specificity of the signal and the 
reproducibility of the assay.  
Real-time PCR was performed in the presence of 1 µL of cDNA template, TaqMan 
gene expression master mix, commercially available TaqMan gene expression assay 
for PGK1 (Hs99999906_m1), 250 nM specific primer mix, 150 nM specific TaqMan 
MGB probe (6-carboxyfluorescein (FAM) dye-labeled) and run on an iCycler IQ 
(Bio-Rad) in a 20 µL reaction volume according to the manufacturer’s instructions. 
PGK1 has been used as a reference gene for this work because it was among the 
most reliable reference genes for peripheral blood gene expression analyses 
(Calligaris et al., BMC Genomics; in press). 
The specific primers and probes have been designed on Nprl3 isoform 1 and on 
TagNprl3 and are indicated on Table 4 and on Figure 18. 
Thermal cycler conditions were as follows: 95°C for 10 min, followed by 40 cycles 
of amplification at 95°C for 15 s and 60°C for 1 min.  
Standard curves of cDNA ranging from 120 ng to 0.2 ng were used to verify that the 
50 ng dilution tested was within the linear range of reaction. Primer efficiency and 
multiplexing efficacy was verified by linear regression to the standard curve with a 
slope near -3.32 representing acceptable amplification efficiency.  
The amplified products were separated on a 2% agarose gel. Results were 
normalized to PGK1 and the initial amount of the template of each sample was 
determined as relative expression versus a pool of healthy control samples used as 
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calibrator. The relative expression of each sample was calculated by the formula 
2exp-∆∆Ct (User Bulletin 2 of the ABI Prism 7700 Sequence Detection System).  
 
Primer (5’   3’) Nprl3 assay TagNprl3 assay 
FW  CCCCACGGCGGGATGCGGGA GTGATCCTGTTTCTTGTCTGGT 
REV TCGCCCGTGTTGCTGGCAGCGT CAGAGCATGCTGTAGCAGTGT 
probe AGCCAGGAGCACCCGGCGTCC GTTATTCTGGCAACAATTTTGGCA 
 
Table 4. List of primers designed for targeting Nprl3 and TagNprl3 and used in the Real-Time 
TaqMan PCR assays. 
 
 
 
 
Figure 18. UCSC Genome Browser visualization of Nprl3 and TagNprl3 TaqMan assays.  
Upper panel: Nprl3 assay designed on second and third exon of Nprl3 isoform 1.  
Lower panel: TagNprl3 assay designed on intronic minisatellite and fourth Nprl3 exon.  
 
 
RNA and protein preparation from blood fractions 
Blood was collected into EDTA tubes and the plasma, the red blood cells and the 
peripheral blood mononuclear cells (PBMC) have been separated starting from the 
whole blood samples by using Ficoll Histopaque gradient following the 
manufacturer’s protocol (SIGMA-ALDRICH). 
To extract total RNA from the blood fractions each sample was added with a proper 
amount of TRIzol reagent (Invitrogen) followed by manufacturer’s protocol. 
A fraction of the total RNA sample was treated with DNase I (Ambion) at 37°C for 1 
hour, and the sample was then purified on RNAeasy mini kit columns (Qiagen). The 
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final quality of RNA sample was tested on the Agilent 2100 bioanalyzer using the 
Eukaryote Total RNA Nano assay. 
The PBMC protein lysate has been prepared adding a proper amount of 2X SDS 
sample buffer (100 mM Tris-HCl (pH 6.8), 4% (w/v) sodium dodecyl sulfate, 0.2% 
(w/v) bromophenol blue, 20% (v/v) glycerol, 200 mM β-mercaptoethanol). The 
protein lysates from whole blood, plasma and red blood cells have been prepared 
according to Lin et al., 2012 (“Whole blood sample preparation” chapter) followed 
by an albumin depletion using trichloroacetic acid (TCA)/acetone (Chen et al., 
2005). 
The obtained precipitates were diluted in a proper amount of 2X SDS sample buffer. 
 
 
Expression plasmids 
Nprl3: pcDNA3 vector containing the full-length DNA sequence of human Nprl3 
isoform 1 and pcDNA3 vector containing coding DNA sequence of human Nprl3 
isoform 2 were kindly provided by Licio Collavin’s laboratory (Consorzio 
Interuniversitario per le Biotecnologie (C.I.B.), Trieste). 
TagNprl3: the full-length DNA sequence of TagNprl3 was amplified from whole 
blood cDNA modified with the GeneRacer 5’ and 3’ adaptors via PCR with the 
GeneRacerTM 5′ Primer (see Table 2) and a gene specific reverse primer: 5’-
TTTTGCTTGGCCTGGCTTTTATCTTGAA-3’. 
The pGEM T-easy-TagNprl3 plasmid was generated by subcloning the cDNA 
sequence into the EcoRI cloning site of the pGEM T-easy cloning vector from 
Promega for sequencing. This cassette was finally cloned into the pcDNA3.1 (-) 
expression vector using the same restriction enzymes.  
Nprl2_Myc: pcDNA3.1- vector containing the coding region of human Nprl2 
amplified from whole blood cDNA. The Myc tag was fused to the C-terminus of the 
protein. 
 
 
Cell culture, transfections and immunoblotting 
HEK 293T (human embryonic kidney) cells were grown in DMEM (GIBCO) 
supplemented with 10% fetal bovine serum (SIGMA-ALDRICH), 100 U/ml 
penicillin and 100µm/ml streptomycin (SIGMA) at 37°C in a humidified CO2 
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incubator. HEK cells were transfected with FuGENE HD Transfection Reagent 
(Promega) following manufacturer instructions. After 48 hours from transfection, 
cells were either collected with 2X SDS sample buffer or analyzed via 
immunofluorescence.  
All the protein lysates have been boiled 5 min at 95°C and analyzed by Western Blot.  
For Western Blot, samples were resolved on SDS/PAGE, and proteins were 
transferred to nitrocellulose membrane (Amersham, GE Healthcare). Membrane was 
blocked with 5% non-fat milk in Tris buffer saline solution (TBST), then incubated 
overnight at 4°C with the following primary antibodies: anti-Nprl3 (ab121346, 
Abcam), anti-β actin (A5441, SIGMA-ALDRICH).  
Proteins were detected by horseradish peroxidase-conjugated secondary antibodies 
(DakoCytomation, Glostrup, Denmark) and ECL reagents (Amersham, GE 
Healthcare).  
 
 
Immunofluorescence 
For immunocytochemistry experiments, cells were fixed in 4% paraformaldehyde 
(SIGMA ALDRICH) for 10 minutes, then washed with phosphate-buffered salin 
solution (PBS) two times, treated with 0.1M glycine for 4 minutes in PBS and 
permeabilized with 0.1% Triton X-100 in PBS for another 4 minutes. After washing 
with PBS and blocking with 0.2% BSA, 1% NGS, 0.1% Triton X-100 in PBS 
(blocking solution), cells were incubated with the indicated antibodies diluted in 
blocking solution for 90 minutes at room temperature. After washes in PBS, cells 
were incubated with labelled secondary antibodies for 60 minutes. For nuclear 
staining, cells were incubated with 1µg/ml DAPI for 5 minutes. Cells were washed 
and mounted with Vectashield mounting medium (Vector). All images were 
collected using a Leica DM6000 fluorescence microscope. 
 
 
Co-immunoprecipitation 
HEK cells were transfected with FuGENE HD Transfection Reagent (Promega) 
following manufacturer instructions. After 24 hours from transfection, cells were 
harvested and lysed in the following buffer supplemented with cOmplete EDTA-free 
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Protease Inhibitor Tablets (Roche): 150 mM NaCl, 50 mM Tris HCl pH 7.4, 0.5% 
NP-40, 1mM EDTA. 
After 30 minutes of lysis at 4°C samples were sonicated twice (7 micron amplitude, 
10 seconds) and then centrifuged 30 minutes, 4°C at maximum speed. Supernatants 
were collected and a fraction was saved as input. Lysated were incubated with 1 µl 
of Myc-Tag (9B11) antibody from Cell Signaling. After 3 hours of incubation, 40 µl 
of Protein G Sepharose beads (GE Healthcare) were added to each sample and 
incubated 1 hour. After washing, beads were dried and eluted in 2X SDS sample 
buffer, boiled 5 min at 95°C and analyzed by Western Blot. 
 
 
Bromodeoxyuridine (BrdU) assay 
Bromodeoxyuridine is a synthetic nucleoside analog of thymidine. BrdU is 
incorporated in living cells during DNA replication (S phase of the cell cycle) and it 
is commonly used to detect proliferating cells. 
HEK cells were transfected with FuGENE HD Transfection Reagent (Promega) 
following manufacturer instructions. As a control, a pcDNA3.1- vector expressing 
GFP was used. After 48 hours from transfection BrdU was added to each plate at a 
final concentration of 15 µg/ml for 1 hour. 
Cells were then fixed in 4% paraformaldehyde (SIGMA ALDRICH) for 10 minutes, 
then washed with phosphate-buffered salin solution (PBS) two times, treated with 
0.1M glycine for 4 minutes in PBS and permeabilized with cold acetone for 30 
seconds. After washing with PBS cells are treated with HCl 3N for 15 minutes to 
separate DNA into single strands so the primary antibody can access the incorporated 
BrdU. After several washes with PBS cells were incubated at 37°C with a blocking 
solution of 1% BSA for 30 minutes, followed by 37°C incubation with an anti-BrdU 
antibody (1:50, SIGMA ALDRICH) and an anti-Nprl3 antibody (1:500, Abcam) in 
blocking solution for 90 minutes. After washes in PBS, cells were incubated with 
labelled secondary antibodies for 60 minutes. For nuclear staining, cells were 
incubated with 1µg/ml DAPI for 5 minutes. Cells were washed and mounted with 
Vectashield mounting medium (Vector). All images were collected using a Leica 
DM6000 fluorescence microscope. 
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Results 
 
 
Blood transcriptomics of PD patients with nanoCAGE 
Thanks to the collaboration with the Director of Clinica Neurologica in Trieste, Prof. 
Gilberto Pizzolato, we collected the peripheral blood of 20 drug-naïve de novo PD 
patients and the peripheral blood of 20 healthy controls (HC) age and sex match. 
In order to analyze the blood transcriptome of the PD samples and compare it to the 
HC we performed nanoCAGE in collaboration with Prof. Piero Carninci’s laboratory 
in RIKEN Institute (Japan). 
Total RNA was purified using PAXgeneTM Blood RNA kit (PreAnalytiX GmbH, 
Qiagen, Hilden, Germany) and underwent two DNaseI digestion steps. Only high 
quality RNAs (RIN ≥ 8) were included in the study as determined with 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA). 
The bioinformatic analysis carried out by Dave Tang, PhD student in Carninci’s 
laboratory, revealed a nanoCAGE tag (27 nt) that was found upregulated by more 
than 50 fold in 30% of PD respect to the remaining patients and HC (0%) controls.  
This tag maps to the third intron of the Nitrogen Permease Regulator-like 3 (Nprl3) 
gene, on the telomeric region of chromosome 16, with coordinates 173660-174239 
(genomic assembly hg19). The multi-mapping nature of this tag is appreciable on 
Figure 19, lower panel suggesting it represents a repetitive region. By Genome 
Browser sequence analysis, we have found that this tag maps on a minisatellite 
sequence of 29 nucleotides repeated 16 times. The mapping is on the (-) strand of 
genomic DNA, in the same direction of Nprl3 transcription. This minisatellite is 
present only in this genome locus and it is human-specific. The most common tag 
sequence is GAGTGTGTGATCCTGTTTCTCAGCGTG. 
Table 5 reports the tag per million (tpm) values of the 40 nanoCAGE samples. 
Samples presenting the highest tag levels are PD2 (30.08), PD4 (23.12), PD7 
(19.42), PD11 (46.05), PD13 (50.88), PD18 (45.57). 
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Figure 19. NanoCAGE-upregulated tag in PD. 
Upper panel: the histogram shows the tag per million (tpm) value (y-axis) of the 40 nanoCAGE 
samples (x-axis) for chr16:173660-174239 region (hg19). High tag-expressing samples are PD2, 
PD4, PD7, PD11, PD13, PD18. 
Lower panel: Genome Browser representation of chr16:173660-174239 region (hg19). RefSeq 
genes are indicated above, showing Nprl3 intronic portion, while patients (blue) and control 
(red) tags are mapped below. The multi-mapping tag suggests this is a repetitive region. 
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Sample tpm 
HC1 1.48 
HC2 1.19 
HC3 2.15 
HC4 0.27 
HC5 1.84 
HC6 1.18 
HC7 1.76 
HC8 0.90 
HC9 0.19 
HC10 0.69 
HC11 2.94 
HC12 1.43 
HC13 0.92 
HC14 1.84 
HC15 3.92 
HC16 0.68 
HC17 1.30 
HC18 0.88 
HC19 2.42 
HC20 0.62 
PD1 0.62 
PD2 30.08 
PD3 4.16 
PD4 23.12 
PD5 0.55 
PD6 0.15 
PD7 19.42 
PD8 0.81 
PD9 5.21 
PD10 2.67 
PD11 46.05 
PD12 1.78 
PD13 50.88 
PD14 1.61 
PD15 1.89 
PD16 0.65 
PD17 1.06 
PD18 45.57 
PD19 3.19 
PD20 2.14 
 
Table 5. NanoCAGE upregulated tag in PD: tag per million (tpm) values for each HC and PD 
sample, mapping on chr16:173660-174239 region (hg19). 
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Figure 20. NanoCAGE tag mapping on minisatellite genomic sequence. This is the minisatellite 
sequence on the minus strand of chr16:173708-174170 region (hg19).  The tag 
GAGTGTGTGATCCTGTTTCTCAGCGTG is indicated in red and it maps 3 times. 
 
 
Variable Number Tandem Repeats at the TSS 
I decided to study in details the minisatellite genomic sequence to unveil the 
molecular basis of the differential expression between high- and low-tag individuals.  
I designed two primers that map externally to the repeated region to obtain the 
amplification of the entire minisatellite from genomic DNAs. Dr. Vlachouli then 
carried out the PCR analysis of PD and HC samples of the same cohort of subjects 
used for nanoCAGE, revealing the presence of two agarose gel bands in a subset of 
individuals, corresponding presumably to a genetic polymorphism (Figure 21 upper 
panel). 
By sequencing these amplicons, we found that the larger fragment consists of 16 
repeats of the 29mer while the shorter fragment consists of 13 repeats of the 29mer. 
More in detail, among the 20 PD patients, 6 subjects (30%) are 16/13 heterozygous. 
Interestingly, these are the ones expressing high-tag counts. Among the 20 HC 1 
subject (5%) is 16/13 heterozygous (sample HC15).  
Figure 21 shows the minisatellite genotype of a high-tag 16/13 (PD13) and of a low-
tag 16/16 (HC10). The schematic representation indicates the three repeats missing 
in allele 13 compared to allele 16.  
We asked ourselves if there is a correlation between high-tag expression, 
heterozygosity and PD incidence, so we decided to analyse the minisatellite genotype 
on new samples from sporadic PD patients and HC, kindly provided by Clinica 
Neurologica (Triest) and by Associazione Donatori di Sangue (Triest).  
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Interestingly, heterozygosity was more prevalent in patients (8 out of 38, about 21%) 
compared to the controls (4 out of 60, about 7%) and to confirm this data we 
performed a larger screening taking 526 sporadic PD patients and 598 HC, kindly 
provided by the Stefano Goldwurm laboratory from Centro Studi Parkinson (Milan) 
and from Associazione Donatori di Sangue (Triest).  
In particular, among PD patients, 101 subjects are 16/13 (19.2%); 7 subjects are 
13/13 (1.3%) and 418 subjects are 16/16 (79.5%). The frequency of the allele 13 in 
PD was 10.9%. Among HC, 111 subjects are 16/13, (18.5%); 4 subjects are 13/13 
(0.7%) and 483 subjects are 16/16 (80.8%). The frequency of the allele 13 in HC was 
9.9%. 
In summary no differences were observed in heterozygosity and allelic frequency 
between PD patients and HC. 
 
 
Figure 21. Genomic PCR amplification reveals that this minisatellite has two allelic forms.  
The upper band corresponds to 16 repeats of the 29mer, while the loIr band to 13 repeats. PD13 
individual (lane 1) is 16/13 heterozygous while HC10 individual (lane 2) is 16/16 homozygous. 
A schematic representation of the two minisatellite alleles is presented below: repeated blocks 
are numbered 1-16 or 1-13 from the right to the left, since the tag mapped on the (-) strand of 
DNA. Same colour means same block sequence. Allele 13 lacks three repeats, corresponding to 
repeats 7-8-9 of allele 16. 
 
 
Luciferase enhancer assay 
An enhancer is a genomic sequence that increases gene transcription by recruiting 
diverse proteins without necessarily being in close proximity to the influenced gene. 
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Based on their relative genomic position to their associated gene, enhancers can be 
proximal or distal.  
Recently, it has been demonstrated that RNA polymerase II can bind a distal 
enhancer producing enhancer-associated transcripts called eRNA (Kim et al., 2010; 
Wang et al., 2011). 
Since minisatellite genotyping allowed us to assess that heterozygosity is linked to 
high-tag expression in our nanoCAGE samples, I hypothesized that the minisatellite 
allele 13 could be an enhancer and the tag-associated transcript an eRNA. 
To address this model, I carried out an enhancer assay taking advantage of pTAL-
Luc vector that expresses firefly luciferase gene under the control of a minimal 
TATA-like promoter. The expression increases when an enhancer sequence is 
inserted in the multiple cloning site upstream to the promoter. 
I tested minisatellite allele 16 and allele 13 in both orientations because enhancer 
activity could be orientation-independent. As a basal control I used an empty pTAL-
Luc vector that expresses minimal levels of luciferase while to normalize each 
transfected well I cotransfected a renilla luciferase-expressing vector in a 10:1 ratio. 
The peak emission of renilla luciferase is 480 nm while for firefly luciferase is 560 
nm. The assay was repeated 4 times. 
Relative firefly luciferase values were highly variable amongst the replicas and there 
is not any significant difference neither between allele 16 and allele 13 nor between 
empty vector and none of the minisatellite constructs. I concluded that minisatellite 
sequence alone could not act as an enhancer. 
 
 
Figure 22. Relative luciferase values of enhancer assay.  
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Minisatellite sequences of both alleles have been cloned into pTAL-Luc vector in both 
orientation (- and + indicate the genomic strand) and assayed for enhancer activity. None of 
them could significatively enhance firefly luciferase activity and there isn’t a difference between 
allele 16 and 13. Firefly luciferase values were normalized on renilla luciferase values. 
 
 
Genome wide association study (GWAS) 
The minisatellite allelic variant carrying 13 repeats has been associated in the 
nanoCAGE assay with high-tag expression, therefore this allele can be defined as an 
eQTL, a locus that modulates a quantifiable phenotypic trait.  
Since the presence of allele 13 is not sufficient to enhance transcription as seen in the 
luciferase assay, I hypothesize that this variant could be associated in linkage 
disequilibrium (LD) with other loci that would contribute to the phenotypic output. 
LD is generally caused by interactions between genes, genetic linkage and the rate of 
recombination, random drift or non-random mating and population structure. 
Genome-wide association studies (GWASs) explore common genetic variation in an 
unbiased manner: the array can capture million of SNPs distributed across the 
genome to find common variations in a selected pool of samples. The power of 
detection depends on the sample size and on the strength of the association. 
I carried out a GWAS to look for variants associated to the minisatellite 
polymorphism. Moreover, this study allows us to discover eventual putative copy-
number variations (CNVs) in the genomes of individuals.  
CNVs are variations in the number of copies of selected portions of genomic DNA 
and are found to be very common in human population. The CNV studies become 
popular since they can account for gene expression levels and, in general, human 
phenotypic variation that might be related to a disease risk (McCarroll, 2008). 
The experiment and the subsequent bioinformatic analysis was carried out as a 
service by Dr. Pio D’Adamo (Consorzio per il Centro di Biomedicina Molecolare – 
CBM, Trieste) on the genomic DNA of PD and HC taking advantage of 
HumanOmniExpressExome BeadChip (Illumina) array. The array is designed to 
capture the greatest amount of common SNP variation. 
I selected 13 individuals from the nanoCAGE assay, subdividing them accordingly to 
the disease/healthy condition and the minisatellite genotype (Table 6). 
Given that only an HC is heterozygous in this pool of samples, I needed to add three 
16/13 healthy individuals that I selected from the cohort obtained from the 
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Associazione Donatori di Sangue (Triest), to compare four 16/16 against four 16/13 
in both PD patients and controls. 
 
Name Condition Genotype Gender 
4PD PD 16/13 F 
11PD PD 16/13 F 
13PD PD 16/13 M 
18PD PD 16/13 M 
5PD PD 16/16 M 
19PD PD 16/16 F 
10PD PD 16/16 F 
14PD PD 16/16 M 
15HC HC 16/13 F 
12CD HC 16/13 F 
28CD HC 16/13 M 
43CD HC 16/13 M 
2HC HC 16/16 F 
5HC HC 16/16 M 
10HC HC 16/16 M 
14HC HC 16/16 F 
 
Table 6. GWAS samples.  
I selected 13 individuals from the nanoCAGE analysis: 8 PD (4 16/13 and 4 16/16) and 5 HC (1 
16/13 and 4 16/16). The missing 16/13 HC were selected from the minisatellite genotype of 
Associazione Donatori Sangue samples: these are indicated as 12CD, 28CD and 43CD. 
 
 
The bioinformatic analysis revealed that there are not common haplotypes in PD 
patients versus HC and in none of the genotype subcategories. 
Interestingly, although no CNVs were found in Nprl3 gene locus, the analysis 
revealed several genes subjected to copy number variation. On Table 7, the relative 
confidence score is indicated for every genomic location detected (genomic assembly 
hg38). 
Further analysis and validation should be done. 
 
Sample Genomic location (hg38) Copy number Gene 
Confidence 
score 
10HC chr5:113327484-113330738 1 MCC 14.672 
10HC chr5:139931629-139931653 1 NRG2 41.034 
10HC chr13:38970825-38992446 1 STOML3 21.842 
10HC chr20:14702391-14732585 1 MACROD2 30.908 
10HC chr2:79516139-79709354 3 CTNNA2 160.845 
10HC chr2:79516139-79709354 3 MIR4264 160.845 
10HC chr13:20425867-20436598 3 CRYL1 43.006 
10HC chr13:20425867-20436598 3 MIR4499 43.006 
Results	  
	   59	  
10HC chr14:20404614-20404736 3 TEP1 16.048 
10HC chr16:28615243-28620752 3 SULT1A1 28.090 
10HC chr17:77381431-77383748 3 SEPT9 17.582 
10PD chr1:74649119-74649321 1 ERICH3 16.074 
10PD chr1:85029067-85029489 1 MCOLN3 21.550 
10PD chr1:91843626-91845778 1 TGFBR3 18.709 
10PD chr2:55544485-55563939 1 SMEK2 17.546 
10PD chr2:55544485-55563939 1 CFAP36 17.546 
10PD chr3:75428675-75605157 1 FAM86DP 20.471 
10PD chr3:121591417-121605219 1 FBXO40 13.749 
10PD chr4:70918817-70921282 1 MOB1B 18.832 
10PD chr4:102792983-102816505 1 UBE2D3 21.241 
10PD chr4:102792983-102816505 1 LOC102723704 21.241 
10PD chr5:19543155-19548361 1 CDH18 17.917 
10PD chr5:37138835-37140209 1 C5orf42 16.326 
10PD chr5:60179360-60186846 1 PDE4D 13.831 
10PD chr5:139931629-139931740 1 NRG2 66.498 
10PD chr6:56917508-56918076 1 DST 16.386 
10PD chr6:78972930-79029367 1 PHIP 22.046 
10PD chr6:144838041-144843858 1 UTRN 18.631 
10PD chr7:3611608-3615700 1 SDK1 15.299 
10PD chr7:18370302-18385624 1 HDAC9 14.877 
10PD chr7:23728916-23729075 1 STK31 15.891 
10PD chr7:48316076-48318680 1 ABCA13 30.944 
10PD chr7:112614215-112631636 1 LOC100996249 19.281 
10PD chr7:112614215-112631636 1 LOC101928012 19.281 
10PD chr9:17462978-17470126 1 CNTLN 13.975 
10PD chr9:105766479-105767091 1 TMEM38B 16.474 
10PD chr10:76361320-76373904 1 C10orf11 9.982 
10PD chr10:91470828-91483101 1 HECTD2 20.172 
10PD chr10:91470828-91483101 1 HECTD2-AS1 20.172 
10PD chr10:91497409-91498808 1 HECTD2 22.071 
10PD chr10:91497409-91498808 1 HECTD2-AS1 22.071 
10PD chr11:32635111-32637615 1 CCDC73 25.538 
10PD chr11:92887296-92887445 1 FAT3 20.323 
10PD chr12:21200019-21207479 1 SLCO1B1 25.176 
10PD chr12:29648262-29648367 1 TMTC1 21.187 
10PD chr12:40076736-40085906 1 SLC2A13 10.556 
10PD chr12:88490666-88524191 1 KITLG 31.882 
10PD chr13:93367328-93384397 1 GPC6 17.221 
10PD chr19:12541214-12542685 1 ZNF564 15.910 
10PD chr19:20626179-20728777 1 ZNF626 46.288 
10PD chr19:38159530-38160276 1 SIPA1L3 15.046 
10PD chr20:32996559-33001677 1 SUN5 12.689 
10PD chr20:58440630-58461828 1 VAPB 32.618 
10PD chr20:58440630-58461828 1 APCDD1L 32.618 
10PD chr7:17959134-18062796 3 PRPS1L1 126.170 
11PD chr3:37979882-37986249 1 CTDSPL 16.171 
11PD chr5:70305696-70307464 1 GUSBP3 20.113 
11PD chr5:97048466-97099320 1 LIX1 58.768 
11PD chr9:89031511-89035754 3 SHC3 33.825 
12CD chr5:151516652-151518156 0 FAT2 19.515 
12CD chr7:91033074-91038222 1 CDK14 17.716 
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12CD chr8:115641238-115642408 1 TRPS1 12.481 
12CD chr10:47543322-47568296 3 BMS1P6 20.984 
12CD chr10:47646751-47703869 3 FAM35DP 52.489 
12CD chr19:43268069-43344686 3 PSG9 34.874 
13PD chr5:151514956-151518156 0 FAT2 12.747 
13PD chr3:89402447-89417171 1 EPHA3 24.117 
13PD chr5:139931633-139931658 1 NRG2 49.735 
13PD chr12:40534583-40538858 1 MUC19 17.207 
13PD chr19:41362173-41365095 1 TMEM91 24.060 
13PD chr19:41362173-41365095 1 B9D2 24.060 
13PD chr15:24619900-24728780 3 NPAP1 27.391 
13PD chr17:44169808-44248497 3 ASB16 53.405 
13PD chr17:44169808-44248497 3 ATXN7L3 53.405 
13PD chr17:44169808-44248497 3 UBTF 53.405 
13PD chr17:44169808-44248497 3 TMUB2 53.405 
13PD chr17:44169808-44248497 3 MIR6782 53.405 
13PD chr17:44169808-44248497 3 ASB16-AS1 53.405 
13PD chr17:44169808-44248497 3 SLC4A1 53.405 
13PD chr22:18969404-18972450 3 DGCR5 17.872 
14HC chr19:20626179-20715228 1 ZNF626 37.743 
14HC chr4:186071932-186134204 3 TLR3 54.038 
14HC chr9:135951231-135955672 3 UBAC1 14.142 
14HC chr21:14613203-14670124 3 LOC388813 10.898 
14PD chr12:40875351-40875963 0 CNTN1 21.682 
14PD chr5:139931607-139931653 1 NRG2 44.833 
14PD chr5:112915301-112947050 3 REEP5 105.297 
14PD chr6:78996260-79029367 3 PHIP 14.566 
14PD chr6:89157027-89162999 3 PM20D2 6.687 
15HC chr1:213009337-213011812 1 ANGEL2 16.549 
15HC chr19:43328006-43372386 1 PRG1 12.743 
15HC chr19:43328006-43372386 1 CD177 12.743 
15HC chr19:43401936-43539189 1 ETHE1 44.754 
15HC chr19:43401936-43539189 1 TEX101 44.754 
15HC chr19:43401936-43539189 1 PHLDB3 44.754 
15HC chr19:43401936-43539189 1 LYPD3 44.754 
15HC chr19:43401936-43539189 1 ZNF575 44.754 
15HC chr5:139931633-139931650 3 NRG2 34.058 
15HC chr10:47543322-47662831 3 BMS1P6 83.480 
15HC chr10:47543322-47662831 3 CTSLP2 83.480 
15HC chr10:47684765-47703869 3 FAM35DP 35.583 
18PD chr5:140232346-140238124 1 CYSTM1 20.919 
18PD chr6:78996260-79029367 1 PHIP 14.152 
18PD chr9:22765106-22819064 1 LINC01239 68.718 
18PD chr10:82879719-82890180 1 NRG3 20.581 
18PD chr2:38963211-38970130 3 ARHGEF33 21.544 
18PD chr3:155481097-155483319 3 PLCH1 28.305 
18PD chr5:139931607-139931740 3 NRG2 84.712 
19PD chr4:157305789-157306780 1 GRIA2 19.050 
19PD chr6:69687698-69690567 1 LMBRD1 13.773 
19PD chr14:35703521-35717282 1 RALGAPA1 27.761 
19PD chr15:55397388-55550755 1 PYGO1 122.328 
19PD chr15:55397388-55550755 1 DYX1C1-CCPG1 122.328 
19PD chr15:55397388-55550755 1 DYX1C1 122.328 
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19PD chr15:55397388-55550755 1 CCPG1 122.328 
19PD chr15:55397388-55550755 1 C15orf65 122.328 
19PD chr5:139931633-139931740 3 NRG2 80.313 
19PD chr19:53521083-53539860 3 ZNF331 36.412 
28CD chr2:4651792-4653622 1 LINC01249 21.012 
28CD chr5:140229786-140238124 1 CYSTM1 37.270 
28CD chr5:177391049-177396392 1 SLC34A1 14.681 
28CD chr9:582371-594579 1 KANK1 27.552 
28CD chr16:28615243-28620752 1 SULT1A1 29.801 
28CD chr19:41362173-41365095 1 TMEM91 22.323 
28CD chr19:41362173-41365095 1 B9D2 22.323 
28CD chr6:78996260-79029367 3 PHIP 17.498 
28CD chr10:26822825-26873049 3 ABI1 45.732 
2HC chr4:157305789-157306780 0 GRIA2 12.835 
2HC chr5:139931633-139931661 1 NRG2 45.618 
2HC chr5:177391049-177396392 1 SLC34A1 14.791 
2HC chr8:7308659-7308718 1 FAM66B 9.637 
2HC chr15:22382531-22468503 1 GOLGA8CP 16.296 
2HC chr15:22382531-22468503 1 GOLGA8EP 16.296 
2HC chr15:34929955-34963958 1 AQR 48.099 
2HC chr3:197800244-197817520 3 LRCH3 23.279 
2HC chr10:42436301-42509794 3 CCNYL2 48.194 
2HC chr10:42436301-42509794 3 LINC00839 48.194 
2HC chr16:23072833-23078389 3 USP31 34.143 
2HC chr16:23098422-23113762 3 USP31 17.293 
43CD chr1:12919838-12920053 0 PRAMEF7 42.778 
43CD chr11:86304402-86305758 0 C11orf73 17.768 
43CD chr1:12907683-12919111 1 PRAMEF7 10.054 
43CD chr5:139931607-139931661 1 NRG2 48.429 
43CD chr8:115641238-115642408 1 TRPS1 13.669 
43CD chr10:46968630-47000252 1 PTPN20B 54.401 
43CD chr19:20626179-20647550 1 ZNF626 12.953 
43CD chr17:44177103-44189067 3 ASB16 13.762 
43CD chr17:44177103-44189067 3 TMUB2 13.762 
43CD chr17:44177103-44189067 3 ASB16-AS1 13.762 
4PD chr1:213002088-213011812 1 ANGEL2 23.198 
4PD chr5:70305696-70308271 1 GUSBP3 20.402 
4PD chr17:67074697-67081830 1 HELZ 42.878 
4PD chr19:20626179-20701612 1 ZNF626 34.735 
4PD chr5:139931633-139931740 3 NRG2 58.503 
4PD chr10:68418846-68429563 3 DNA2 34.027 
4PD chr16:28618318-28620752 3 SULT1A1 13.991 
5HC chr6:78972930-79029367 0 PHIP 36.350 
5HC chr3:75428675-75605157 1 FAM86DP 12.168 
5HC chr3:155481097-155487290 3 PLCH1 40.465 
5HC chr5:139931607-139931691 3 NRG2 77.170 
5HC chr18:63201728-63205702 3 BCL2 9.505 
5PD chr5:151514956-151518156 0 FAT2 21.616 
5PD chr1:174797867-174800121 1 RABGAP1L 16.765 
5PD chr12:31390640-31394235 3 DENND5B 18.478 
5PD chr15:101695029-101717607 3 TARSL2 42.299 
5PD chr16:6011798-6036851 3 RBFOX1 61.325 
5PD chr16:6044487-6046935 3 RBFOX1 27.379 
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Table 7. CNV bioinformatic analysis.  
The genomic coordinates of the CNV (genomic assembly hg38), the number of copies, the 
included gene and the confidence score are indicated. 
 
 
Tag-containing transcript identification and validation 
 
Identification of tag-containing transcripts 
To identify the tag-containing transcripts I took advantage of 3’Rapid Amplification 
of cDNA Ends (RACE) applying this technique to the PD sample that presented the 
highest amount of tags on the nanoCAGE assay (PD13, Figure19). 
PD13 RNA was retrotranscribed into cDNA modified with the GeneRacer 3’ adaptor 
using poly-T primer and the first-step RT-PCR was carried out using the GeneRacer 
3’ Primer and a forward primer corresponding to the tag sequence (Figure 23A). 
Nested RT-PCR, performed using the GeneRacer 3’ Nested Primer and the same 
forward primer, allowed amplification of a major product (about 2000 bp) (Figure 
23E).  
Subcloning and sequencing of this fragment revealed a new Nprl3 isoform with the 
TSS in the third intron of Nprl3 gene (Figure 23B). 
I performed the 3’RACE assay several times and along this major product of 
amplification (that was always present in the PCRs) I have been able to subclone and 
sequence other minor products that could have an important biological meaning. 
I identified four Nprl3-Hemoglobin A1 chimeric transcripts that I called transalpha 
1-4. The breakpoints of these transcripts involve the intronic minisatellite sequence 
(2-4 repeats are transcribed) and the third exon of hemoglobin 1A (HBA1). Only in 
one case (transalpha4) I could observe a more complex transplicing composed by 
minisatellite intronic sequence spliced to the subsequent two exons of Nprl3 
interrupted by part of the second and all the third exon of HBA1 (Figure 24). 
As suggested by Unneberg and Claverie, 2007, chimeric transcripts may be the result 
of close encounters of active genes and could represent functional products or 
“noise” in the transcription process. Nprl3 gene lies in the distal region of the short 
arm of chromosome 16, which has been largely studied due to the presence of alpha 
globin gene cluster (Vyas et al., 1995). In particular HS-40, the major distal enhancer 
5PD chr16:6098295-6285091 3 RBFOX1 376.524 
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of alpha globin cluster lying in the fourth intron of Nprl3, directly interacting with 
alpha gene promoters via chromatin looping, as proposed by Li, 2006 and 
demonstrated by Vernimmen et al., 2009. 
This physical interaction may explain the chimeric transcripts formation but further 
studies will be necessary to unveil their functional role. Unfortunately, I could not be 
able to validate these chimeric transcripts due to the high abundance of HBA1 
transcript in blood RNA samples. 
I decided to repeat the 3’RACE experiment to confirm the existence of the new 
Nprl3 isoform. To validate the TSS located in the minisatellite I performed 5’RACE. 
To this purpose, I choose another high tag-expressing PD blood sample (PD11, 
Figure 19). 
After the ligation of a synthetic RNA oligonucleotide to the 5’ end of decapped RNA 
and retrotrascription into cDNA modified with the GeneRacer 3’ adaptor using poly-
T primer, in the 3’RACE experiment the first-step and the nested RT-PCR have been 
carried out in the same conditions as for PD13. 
In the 5’RACE experiment first-step RT-PCR was carried out using the GeneRacer 
5’ Primer and a reverse primer located to the fourth exon of Nprl3 gene. 
5’RACE nested RT-PCR was performed using the GeneRacer 5’ Nested Primer and 
a nested reverse primer spanning the fourth Nprl3 exon and the transcribed intronic 
sequence found with 3’RACE (Figure 23C). 
The 3’RACE gel run revealed a 2000 bp band and by subcloning and sequencing it I 
could confirm the result obtained with PD13 sample (data not shown). Moreover the 
5’RACE gel run revealed the amplification of a major product (about 200 bp) 
(Figure 23F) and the subcloning and sequencing of this fragment confirmed that the 
TSS of this new Nprl3 isoform (TagNprl3) is located in the minisatellite sequence of 
Nprl3 third intron (Figure 23D).  
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Figure 23. Identification of the tag containing transcripts by 3' RACE-PCR analysis and 
validation by 5' RACE-PCR analysis.  
A) UCSC Genome Browser representation of the 3’ RACE_FW primer (double mapping on the 
minisatellite sequence).  
B) Sequence derived from 3’RACE product visualized with the USCS Genome Browser. 
3’RACE validated the transcriptional activity of the minisatellite located in Nprl3 third intron.  
C) UCSC Genome Browser representation of the 5’ RACE_REV and 5’RACE_nestedREV 
primers.  
D) Sequence derived from 5’RACE product visualized with the USCS Genome Browser. 
5’RACE validated the transcription start site located in the intronic minisatellite.  
E) 5’RACE performed on first-strand cDNA prepared from total RNA from PD11 whole blood. 
PCR products were analyzed on a 1% agarose gel with EtBr staining.  
F) 3’RACE performed on first-strand cDNA prepared from total RNA from PD13 whole blood.  
A.#
B.#
C.#
D.#
E.#
1500#bp#9##
2000#bp#9##
M#####PD13# F.#
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Fig.2 Identification of the tag containing transcripts by 3' RACE-PCR analysis and validation by 5' RACE-PCR analysis 
A.  UCSC Genome Browser representation of the 3’ RACE_FW primer (double mapping on the minisatellite sequence) 
B.  Sequence derived from 3’RACE product visualized with the USCS Genome Browser. 3’RACE validated the transcriptional 
activity of the minisatellite located in Nprl3 third intron. 
C.  UCSC Genome Browser representation of the 5’ RACE_REV and 5’RACE_nestedREV primers 
D.  Sequence derived from 5’RACE product visualized with the USCS Genome Browser. 5’RACE validated the transcription start 
site located in the intronic minisatellite. 
E.  5’RACE performed on first-strand cDNA prepared from total RNA from PD11 whole blood. PCR products were analyzed on 
a 1% agarose gel with EtBr staining. 
F.  3’RACE performed on first-strand cDNA prepared from total RNA from PD13 whole blood. PCR products were analyzed on 
a 1% agarose gel with EtBr staining. 
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PCR products were analyzed on a 1% agarose gel with EtBr staining.  
 
 
 
Figure 24. Identification of chimeric products by 3' RACE-PCR analysis.  
A) Schematic representation of chimeric products found with 3’RACE analysis. The white block 
indicates the scale. In blue, Nprl3 intronic part; in green, Nprl3 exonic part; in red, Hba1 exonic 
part.  
B) UCSC Genome Browser representation of 5’ ends of the chimeric transcripts on Nprl3 gene.  
C) UCSC Genome Browser representation of 3’ ends of the chimeric transcripts on Hba1 gene.  
 
 
 
I then focused my attention on the TSS to identify the minisatellite repeat that 
contains the core promoter. I thus discovered that the +1 nucleotide of the transcript 
is a cytosine located on repeat number 11 (Figure 25). 
The most commonly occurring core promoter motif in mammalian cells is the Inr 
initiator which consensus sequence is YYA+1NWYY in humans (Javahery et al., 
1994). However, the sequence for TagNprl3 transcription is TC+1TTTCT which 
strongly resemble a TCT motif (YC+1TYTYY), a key component of an RNA 
polymerase II system that is directed toward the expression of ribosomal protein 
genes as well as other genes encoding factors involved in protein synthesis (Parry et 
al., 2010).  
Despite the high sequence homology between the different repeats, the consensus 
TC+1TTTCT is present only in the eleventh repeat and could explain the specificity 
of transcription start, however it is present both in 16 and 13 repeats alleles so it 
could not explain the differential expression between 16/13 and 16/16 individuals. 
Fig.3 Identification of chimeric products by 3' RACE-PCR analysis 
A.  Schematic representation of chimeric products found with 3’RACE analysis. The white block indicates the scale. In blue, 
Nprl3 intronic part; in green, Nprl3 exonic part; in red, Hba1 exonic part. 
B.  UCSC Genome Browser representation of 5’ ends of the chimeric transcripts on Nprl3 gene. 
C.  UCSC Genome Browser representation of 3’ ends of the chimeric transcripts on Hba1 gene. 
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Figure 25. Schematic representation of minisatellite 16 repeats.  
The transcription starts on the cytosine at position 22 in the eleventh repeat. The TC+1TTTCT 
consensus present only in this repeat strongly resemble a TCT motif (YC+1TYTYY), a key 
component of an RNA polymerase II system that is directed toward the expression of ribosomal 
protein genes as well as other genes encoding factors involved in protein synthesis (Parry et al., 
2010). The 13-repeats allele lacks lines 7-8-9 and so TC+1TTTCT consensus is conserved.  
 
 
 
TagNprl3 transcript validation 
To validate the TagNprl3 transcript identified with RACE, I designed a reverse 
primer in the 3’UTR region. I performed RT-PCR by using this primer in 
combination with the same forward primer of the 3’RACE assay, which corresponds 
to the nanoCAGE tag sequence (Figure 26A). Together with PD13 16/13, I decided 
to test another heterozygous high-expressing tag sample (PD2, 16/13, Figure 19) and 
a homozygous low-expressing tag sample (HC14, 16/16, Figure 19). 
As expected, the amplicon is around 2000 bp and by sequencing I confirmed the 
identity of the TagNprl3 sequence. Together with validating TagNprl3 transcript, I 
also proved that TagNprl3 is indeed differentially expressed between high- and low-
expressing tag samples, as expected (Figure 26B).  
On the contrary, by performing an RT-PCR with Nprl3 isoform 1 primers, its 
expression is quite comparable among the three samples (Figure 26C).  This pair of 
primers will be used in the Real-Time TaqMan PCR. 
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Figure 26. Validation of TagNprl3 transcript.  
A) UCSC Genome Browser representation of the FW primer (double mapping on the 
minisatellite sequence) and the REV primer used for TagNprl3 validation.  
B) TagNprl3 RT-PCR performed on first-strand cDNA prepared from total RNA from PD2, 
PD13 and HC14 whole blood. PCR products were analyzed on a 1% agarose gel with EtBr 
staining. The main 2000 bp product corresponds to TagNprl3 and its expression is barely 
detectable in HC14 individual (16/16, low-tag expressing) wherease is intense in PD2 and PD13 
(both 16/13, high-tag expressing).  
C) Nprl3 RT-PCR performed on the same samples (PD2, PD13 and HC14).  PCR products were 
analyzed on a 1% agarose gel with EtBr staining. The 200 bp product corresponds to Nprl3 and 
its expression is comparable among the three individuals. 
 
PD2#########PD13######HC14######blank###########M#
9#2000#bp##
A.#
B.#
Fig.5 Validation of TagNprl3 transcript.  
A.  UCSC Genome Browser representation of the FW 
primer (double mapping on the minisatellite 
sequence) and the REV primer used for TagNprl3 
validation. 
B.  RT-PCR performed on first-strand cDNA prepared 
from total RNA from PD2, PD13 and HC14 whole 
blood. PCR products were analyzed on a 1% 
agarose gel with EtBr staining. The main 2000 bp 
product corresponds to TagNprl3 and its expression 
is barely detectable in HC14 individual (16/16, low-
tag expressing) wherease is intense in PD2 and 
PD13 (both 16/13, high-tag expressing). 
PD2#########PD13######HC14######blank###########M#
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TagNprl3 expression is linked to minisatellite genotype 
To assess if high TagNprl3 expression correlates with high nanoCAGE tag 
expression I selected 19 RNA samples that have been used for the nanoCAGE 
analysis: 6 PD high-expressing tag, 6 PD low-expressing tag, 6 HC low-expressing 
tag and the HC with the highest number of tags. 
I carried out Real-Time TaqMan RT-PCR with the assays for TagNprl3 and Nprl3 
mRNAs. I took advantage of PGK1 as invariant gene for normalization. 
Nprl3 expression levels are quite variable among different samples but show no 
correlation with nanoCAGE tag expression or disease condition (Figure 27A). 
On the other hand, TagNprl3 high expression is strongly correlated with high 
nanoCAGE tag expression while it is low when tag was almost undetectable. 
Unexpectedly, HC15 expresses high levels of TagNprl3 (Figure 27B).  
It is then important to clarify whether TagNprl3 high expression correlates with the 
16/13 minisatellite genotype or with PD.  
To address this crucial question I need to collect a larger number of HCs with 16/13 
genotype.  
To this purpose, I created an independent set of samples (PD from “Clinica 
Neurologica di Trieste” and “Telethon Biobank”, HC from “Associazione Donatori 
Sangue Trieste”) that have been genotyped for the minisatellite sequence in order to 
collect a sufficient amount of heterozygous individuals. This set of samples is 
composed by 6 PD 16/16, 4 PD 16/13, 6 HC 16/16 and 4 HC 16/13 (details on Table 
8). 
I then performed a Real-Time TaqMan RT-PCR in the same conditions as for the 
validation set and with the same assays (TagNprl3, Nprl3 and PGK1 for 
normalization). 
Nprl3 expression is variable among individuals but I could not find any correlation 
between its expression and genotype or disease state (Figure 27C). 
TagNprl3 expression is clearly linked to 16/13 minisatellite genotype being highly 
induced in these individuals compared to homozygous however, I could not find any 
correlation with PD (Figure 27D). 
In summary, TagNprl3 is a new Nprl3 isoform with a new TSS in its third intron and 
its expression is highly induced by the genotype condition of the minisatellite lying 
in this intron. 
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Experiment Minisatellite Genotype Sample Name 
2C 
5C 
7C 
8C 
10C 
16/16 
14C 
16/13 15C 
1PD 
6PD 
8PD 
9PD 
10PD 
16/16 
19PD 
2PD 
4PD 
7PD 
11PD 
13PD 
Validation 
16/13 
18PD 
PD_C2616 
PD_M2371 
PD_Z0411 
PD_S1613 
PD_T0770 
16/16 
PD_C2766 
PD_025 
PD_022 
PD_Z0397 
16/13 
PD_G1593 
C_49AB 
C_51PR 
C_52FC 
C_54MK 
C_47IC 
16/16 
C_48MK 
C_12CD 
C_28CD 
C_43SB 
Independent 
16/13 
C_43CS 
 
Table 8. List of Real Time TaqMan PCR blood samples and their minisatellite genotype.  
The two samples in bold have been used for the fractionation experiment.    
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Figure 27. TagNprl3 upregulation in blood is linked to 16/13 minisatellite genotype.  
Real-Time TaqMan PCR normalized with PGK1 assay. Fold change is indicated on the y-axis. 
PD are indicated in red and HC in blue.  
A) Nprl3 assay on selected nanoCAGE samples. Canonical Nprl3 isoform expression is variable 
among individuals but it is independent from minisatellite genotype or healthy/pathological 
state.  
B) TagNprl3 assay on selected nanoCAGE samples reveals that its high expression is linked to 
16/13 minisatellite genotype.  
C) Nprl3 assay on an independent sample set (PD and HC, 16/13 and 16/16, see Table 8). I could 
confirm that Nprl3 expression is independent from minisatellite genotype or 
healthy/pathological state.  
D) TagNprl3 assay on an independent sample set (PD and HC, 16/13 and 16/16, see Table 2) 
confirmed that all 16/13 individuals (both PD and HC) express high levels of TagNprl3. 
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Biological function of TagNprl3 
 
TagNprl3 encodes for a nucleo-cytoplasmic protein  
Nprl3 gene has 5 annotated different alternative splicing transcripts. In particular, 
isoforms 2-5 are predicted to translate a shorter Nprl3 protein, starting from an 
alternative AUG. Until now, only Nprl3 isoform 1 (NM_001077350) is known to 
encode for a protein of 64 kDa, while truncated forms were undetectable in several 
cell types (Lunardi et al., 2009). The coding sequence of TagNprl3 corresponds to 
the coding sequence of Nprl3 isoform 3 (NM_001243247) but their UTRs are 
different. Nprl3 isoform 3 is an N-terminal truncated (Δ1-78 aminoacids) Nprl3 
protein. 
To investigate the function of TagNprl3 I cloned the full-length sequence into 
pcDNA3.1- expression vector.  
First, I wanted to investigate whether the TagNprl3 transcript encodes for the N-
terminal-truncated Nprl3 protein. To this purpose I transiently transfected HEK 293T 
cells with TagNprl3 using Nprl3 as control. By taking advantage of an antibody 
against Nprl3 (Abcam) I observed that TagNprl3 encodes for a 60 kDa protein while 
full-length Nprl3 protein is of the expected size (64 kDa, lane 2) (Figure 28A). 
Then I studied TagNprl3 subcellular localization with an immunofluorescence assay 
on transiently transfected HEK 293T cells and I observed a similar nucleo-
cytoplasmic distribution for Nprl3 and TagNprl3 (Figure 28B). 
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Figure 28. Analysis of the exogenous expression of TagNprl3 reveals a 60 kDa protein that has a 
nucleo-cytoplasmic localization.  
A) The full-length transcript of TagNprl3 was cloned into an expression vector and transiently 
transfected in HEK 293T cells. Taking advantage of an antibody against Nprl3 (Abcam) I could 
demonstrate that TagNprl3 translation give rise to a protein product of about 60 kDa. HEK 
cells transiently transfected with canonical Nprl3 have been used to appreciate the molecular 
weight difference. β actin was used as a loading control.  
B) Immunofluorescence analysis on HEK 293T cells transiently transfected with Nprl3 or 
TagNprl3 and stained with anti-Nprl3 antibody reveals that the two proteins have a similar 
nucleo-cytoplasmic distribution. 
 
 
 
TagNprl3 binds Nprl2 
It has been demonstrated that Nprl3 forms an heterodimer with its partner Nprl2 and, 
together with DEPCDC5, they form a protein complex called GATOR1 in mammals, 
which in turns is involved in many cellular processes such as stimulation of protein 
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synthesis, growth, metabolism and the inhibition of autophagy (Bar-Peled et al., 
2013). 
To assess if TagNprl3-encoded protein (that corresponds to Nprl3 isoform 3) could 
interact with Nprl2 a co-immunoprecipitation assay has been set up by co-
transfecting HEK cells with Nprl2_MYC and TagNprl3. As control I used Nprl3 
isoform 1 and Nprl3 isoform 2: the former is the canonical Nprl3 isoform involved in 
GATOR1 complex, the latter is a N-terminal truncated (Δ1-179 aminoacids) protein-
coding isoform. 
Our hypothesis is that Nprl3 isoform 2 should not co-immunoprecipitate because it 
lacks the N-terminal longin domain that should dimerize with the N-terminal longin 
domain of Nprl2, according to Levine et al., 2013.  
As shown in Figure 29, Nprl2 unexpectedly interacts with all the three different 
Nprl3 isoforms meaning that there could be at least one other domain involved in the 
dimerization. Moreover, Nprl3 isoform 1 transcript encodes, to a lesser extent, for all 
the other isoforms by alternative translation initiation. Interestingly, Nprl2 showed a 
higher affinity for N-terminal truncated 60 kDa protein encoded by Nprl3 isoform 3, 
the protein encoded by TagNprl3 (Figure 29).  
 
 
Figure 29. Co-immunoprecipitation of Nprl2 with Nprl3 isoforms.  
A) Schematic representation of the three Nprl3 isoforms tested for Nprl2 interaction. The sense 
of transcription is from right to left.  
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Fig.8 Co-immunoprecipitation of Nprl2 with Nprl3 isoforms  
A.  Schematic representation f the three Nprl3 isoforms tested for Nprl2 interaction. 
B.  Western blot showing the co-immunoprecipitation assay in Hek 293T cells transiently transfected with Nprl2 
and one of the three Nprl3 isoforms. After 24 h from transfection, cell lysates have been incubated with Myc 
antibody (Cell Signaling) that recognize the C-terminal tag of Nprl2. Protein G Sepharose beads have been 
used to precipitate the protein complexes bound by Myc antibody that have been tested for Nprl3 isoforms 
presence by western blot. Surprisingly, Nprl2 co-immunoprecipitates with all the three Nprl3 isoforms. 
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TagNprl3#
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B) Western blot showing the co-immunoprecipitation assay in HEK 293T cells transiently 
transfected with Nprl2 and one of the three Nprl3 isoforms. After 24 h from transfection, cell 
lysates have been incubated with Myc antibody (Cell Signaling) that recognize the C-terminal 
tag of Nprl2. Protein G Sepharose beads have been used to precipitate the protein complexes 
bound by Myc antibody that have been tested for Nprl3 isoforms presence by western blot. 
Surprisingly, Nprl2 co-immunoprecipitates with all the three Nprl3 isoforms. 
 
 
TagNprl3 inhibits proliferation 
By carrying out co-immunoprecipitation experiments, I observed that plates 
containing TagNprl3-transfected cells showed a marked decrease in cell counts.  
It has been already demonstrated that Nprl3 inhibits proliferation (Lunardi et al., 
2009) and I therefore took advantage of the BrdU assay to test whether TagNprl3 
was exerting the same effect.  
HEK 293T cells were transfected with plasmids expressing GFP, Nprl3 or TagNprl3 
and after 48 hours assayed with BrdU. By immunofluorescence with anti-BrdU 
antibodies, I found that Nprl3- and TagNprl3-transfected cells showed a significative 
decrease in the rate of proliferation compared to controls: 40% of GFP positive cells 
were growing in control experiment while only about 15% of Nprl3-overexpressing 
cells and about 20% of TagNprl3 cells incorporated BrdU. 
I thus confirmed Lunardi et al. data and proved that TagNprl3 has a similar function 
in inhibiting cell proliferation. 
 
Figure 30. TagNprl3 retains the ability of the full-length protein to inhibit proliferation.  
Nprl3 and TagNprl3 inhibit BrdU incorporation. A vector expressing GFP was transfected as a 
control. The y axis indicates the % of BrdU positive cells in the transcfected population. 
Number of replica=5. 
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TagNprl3 overexpression has no effect on mTORC1 
As part of GATOR1 complex, Nprl3 plays an important role in the negative 
regulation of mTORC1 and its expression alterations might influence downstream 
effectors. I therefore decided to analyze by western blot two different pathways that 
are under the control of mTORC1: protein synthesis, through the ribosomal protein 
S6 kinase (S6K) and 4E-binding protein 1 (4E-BP1) that are phosphorylated by 
active mTORC1, and autophagy, through microtubule-associated protein light chain 
3 (LC3) that is converted in the active form if the process is stimulated.  
As shown in Figure 31, mTORC1 stimulates protein synthesis through S6K 
stimulation and 4E-BP1 inhibition and at the same time inhibits autophagy. 
GATOR1 complex in turn inhibits mTORC1, as well as the common antitumoral 
drug Rapamycin that was used as a control of pathways alteration. 
 
Figure 31. mTORC1 effectors. The involved molecular pathways are indicated. GATOR1 
complex directly inhibits mTORC1 as well as Rapamycin drug (not indicated). The proteins 
that have been assayed by western blot are circled in red (adapted from Johnson et al., 2013). 
 
 
As shown in Figure 32, the effect of Rapamycin inhibiting mTORC1 is evident in the 
loss of phosphorylation of both p70 S6K and 4EBP1. However this treatment is not 
sufficient to trigger autophagy as the conversion of soluble LC3-I (19 kDa) to active 
lipid bound LC3-II (17 kDa) is not visible. 
Upon Nprl3 and TagNprl3 I could not observe alterations in the phosphorylation 
state of S6K nor 4EBP1, indicating that mTORC1 is not inhibited. On the other 
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hand, I could observe the appearance of a faint signal corresponding to active LC3-II 
in TagNprl3-transfected sample however, this effect must be further investigated. 
 
 
Figure 32. mTORC1 downstream effectors are not altered upon Nprl3 nor TagNprl3 
overexpression. HEK 293T cells have been transiently transfected with Nprl3, TagNprl3 or with 
empty vector. As a control of mTORC1 inhibition, cells were treated for 1 hour with 2 µM 
Rapamycin. The western blot analysis of p-p70 S6K and p-4EBP1, that are protein synthesis 
markers downregulated upon mTORC1 inhibition, indicates that Nprl3 or TagNprl3 
overexpression alone is not sufficient to trigger this effect. The autophagy marker LC3 indicated 
that autophagy is not stimulated but the appearance of active LC3-II is not detectable neither 
upon Rapamycin treatment. β-actin was used as a normalization control. 
 
 
RBCs are the main source of TagNprl3 in blood 
I wanted to assess what is the main source of TagNprl3 expression among the three 
different blood components: peripheral blood mononuclear cells (PBMC), red blood 
cells (RBC) and plasma.  
I previously showed that TagNprl3 expression is not linked to PD but is driven by 
genetic heterozygosity of the minisatellite. Therefore I decided to take advantage of 
two 16/13 HCs part of the Real-Time TaqMan PCR validation set (C_43_CS and 
C_12_CD, see Table 8) to be compared to two 16/16 HC (MB and RC).  
The blood has been collected into EDTA tubes and then the three blood fractions 
have been separated with Histopaque®-1077 reagent from SIGMA-ALDRICH. After 
RNA extraction, I prepared cDNA and performed a Real-Time TaqMan RT-PCR 
with the assays TagNprl3, Nprl3 and PGK1 for normalization. 
Nprl3 and TagNprl3 expression is quite exclusive of RBC fraction and, in 
heterozygous individuals, it is highly induced. PBMC express low levels of Nprl3 
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while TagNprl3 was undetectable except for individual C_43_CS. However, for this 
sample I cannot exclude a contamination due to the high induction of TagNprl3 
mRNA (Figure 33A, 33B). Both Nprl3 and TagNprl3 were undetectable in plasma 
(data not shown). 
The main source of TagNprl3 are the RBCs and surprisingly, its expression revealed 
to be higher that the canonical Nprl3 isoform 1 in homozygous individuals. 
 
 
TagNprl3 protein is upregulated in the RBCs of heterozygous 
individuals 
I wanted to assess if TagNprl3 expression in RBCs gives rise to a protein product 
that is highly induced in heterozygous individuals. I thus prepared protein lysates 
from the RBC of MB 16/16 healthy individual, and from two 16/13 healthy 
individuals (C_43_CS and C_12_CD) that have been previously assayed for 
TagNprl3 RNA. 
These protein lysates have been assayed by western blot: with anti-Nprl3 antibody I 
could detect a band of about 60 kDa in all the human samples. Moreover, this protein 
is highly induced in the two 16/13 individuals suggesting that TagNprl3 is translated 
in vivo and its expression is upregulated by heterozygous minisatellite genotypes 
(Figure 33). 
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Figure 33. Red blood cells (RBC) are the main source of TagNprl3 expression in blood and 
16/13 minisatellite genotype induces TagNprl3 transcript and protein upregulation.  
For these experiments 4 HC have been chosen: 2 heterozygous (C_43_CS and C_12_CD) and 2 
homozygous (MB and RC). Whole blood samples have been fractionated with Histopaque®-1077 
reagent (SIGMA-ALDRICH) and the total RNAs have been extracted with TRIzol reagent 
(Invitrogen). After cDNA preparation I performed two Real-Time TaqMan assays: 
A) Nprl3 assay shows that its expression is variable among the four individuals and ubiquitous 
in the cell fractions, although prevalent in RBC. 
B) TagNprl3 assay shows that its expression seems to be exclusive of RBC (except from 
C_43_CS PBMC) and it is highly induced in the RBC of heterozygous individuals.  
C) Western blot on RBC fraction protein lysate of a homozygous individual vs two heterozygous 
individuals shows that TagNprl3 protein exists in vivo and its induction by 16/13 genotype 
corresponds to a higher protein production. HEK cells transiently transfected with TagNprl3 or 
Nprl3 have been used as molecular weight control. Membranes have been incubated with anti-
Nprl3 antibody (Abcam) and anti-β actin antibody has been used as normalizator.  
PBMC: Peripheral Blood Mononuclear Cells; RBC: Red Blood Cells; WB: Whole Blood. 
Fig.9 Red blood cells (RBC) are the main source of TagNprl3 expression in blood and 16/13 mi isatellite genotype induces 
TagNprl3 transcript and protein u regulation 
For these exp rim nts 4 HC have been chosen: 2 heterozygous (C_43_CS and C_12_CD) and 2 homozygous (MB and RC). 
Whole blood samples have been fractionated with Histopaqu ®-1077 reagent (SIGMA-ALDRICH)  and the total RNAs have been 
extracted with TRIzol reagent (Invitrogen). After cDNA preparation we p rformed two Real-Time TaqMan assays: Nprl3 assay 
(A.) shows that its expression is variable among the four individuals and ubiquitous in the cell fractions, although prevalent in 
RBC; TagNprl3 assay (B.) shows that pres ion seems to be xclusive of RBC (except from C_43_CS PBMC) and it is highly 
induced in the RBC of heterozygous individuals. 
C. Western blot on RBC fraction protein lysate of an homozygous individual vs two het rozygous individuals shows that TagNprl3 
protein exists in vivo and its induction b  16/13 genotyp  corresponds to a higher protein production. Hek cells transiently 
transfected with TagNprl3 or Nprl3 have been used as molecular weight control. Membranes have been incubated with anti-Nprl3 
antibody (Abcam) and anti-β actin antibody has been used as normalizator.  
PBMC: Peripheral Blood Mononuclear Cells; RBC: Red Blood Cells; WB: Whole Blood 
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TagNprl3 expression in other tissues 
I then asked if TagNprl3 expression could be detectable in other tissues. To this 
purpose I interrogated Zenbu database on human FANTOM5 (Functional Annotation 
of the Mammalian Genome, established by Dr. Hayashizaki and his colleagues in 
2000, Riken, Japan). 
Zenbu is a data integration, data analysis, and visualization system enhanced for 
RNAseq, ChipSeq, CAGE and other types of next-generation-sequence-tag (NGS) 
based data.  
I interrogated the database at the genomic coordinates around TagNprl3 TSS: 
chr16:173854-173884 (hg19) and observed that the highest values of tag per million 
(tpm) are present in blood-derived samples. 
On Table 10 I report all the cell types that have a tpm value in this genomic position. 
Although Nprl3 expression is detectable in all cell types and higher in blood tissue, 
TagNprl3 seems to be expressed exclusively in blood. However, validation is needed 
as well as comparison with analysis of 16/13 individuals. 
 
cell type tpm 
Whole blood (ribopure), donor090309, donation2 : CNhs11671 ctss 2.92 
Whole blood (ribopure), donor090309, donation1 : CNhs11675 ctss 2.57 
Whole blood (ribopure), donor090612, donation2 : CNhs11673 ctss 2.39 
Whole blood (ribopure), donor090612, donation1 : CNhs11672 ctss 1.69 
Whole blood (ribopure), donor090309, donation3 : CNhs11948 ctss 1.16 
blood, adult, pool1 : CNhs11761 ctss 1.12 
mesenchymal stem cells (adipose derived), adipogenic induction, 00hr30min, biol rep2 : CNhs13426 ctss 0.67 
CD34 cells differentiated to erythrocyte lineage, biol rep1 : CNhs13552 ctss 0.47 
Myoblast differentiation to myotubes, day12, Duchenne Muscular Dystrophy donor3 : CNhs14613 ctss 0.41 
hIPS +CCl2, biol rep1 : CNhs14217 ctss 0.34 
Schwann Cells, donor3 : CNhs12621 ctss 0.31 
Whole blood (ribopure), donor090612, donation3 : CNhs11949 ctss 0.27 
COBL-a rinderpest(-C) infection, 06hr, biol rep3 : CNhs14437 ctss 0.26 
Whole blood (ribopure), donor090325, donation2 : CNhs11076 ctss 0.26 
MCF7 breast cancer cell line response to EGF1, 01hr40min, biol rep3 : CNhs12743 ctss 0.21 
CD34 cells differentiated to erythrocyte lineage, biol rep2 : CNhs13553 ctss 0.18 
SABiosciences XpressRef Human Universal Total RNA, pool1 : CNhs10610 ctss 0.16 
Astrocyte - cerebral cortex, donor2 : CNhs11960 ctss 0.16 
lung, fetal, donor1 : CNhs11680 ctss 0.16 
Natural Killer Cells, donor3 : CNhs12001 ctss 0.11 
spleen, fetal, pool1 : CNhs10651 ctss 0.09 
Universal RNA - Human Normal Tissues Biochain, pool1 : CNhs10612 ctss 0.07 
kidney, fetal, pool1 : CNhs10652 ctss 0.07 
 
Table 10. FANTOM5 tag per million values for human samples at genomic location 
chr16:173854-173884 (hg19). 
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Discussion 
 
PD is a neurodegenerative disorder that affects 1-2 % of all population above the age 
of 65. PD is a systemic, multifactorial disease caused by both environmental and 
genetic factors. The population aging together with the exposure to industrial and 
rural toxins seemed to be the main cause of its prevalence. 
Unfortunately, at present there is no pharmacological treatment that can revert or 
slow neurodegeneration. Its diagnosis remains difficult since no standard tests are 
available. Patients are usually diagnosed at a late stage of PD, when motor symptoms 
appear and the loss of DA-producing cells in the SNc is about 60-70% (Dauer and 
Przedborski, 2003). 
The strong need of an effective and early diagnosis has stimulated PD research 
towards a quest for novel biomarkers by gene expression analysis. In this context, 
since PD is a systemic disease, alterations associated to the pathology should be 
found outside the central nervous system.  
One of the most promising tissues for biomarker discovery is blood since it is 
accessible and easy to collect with a fast and reproducible procedure. Furthermore, 
many works have interrogated the blood transcriptome of neurodegenerative disease 
patients, including PD, in search for a gene signature of the disease (some examples 
are Infante et al., 2015; Molochnikov et al., 2012; Scherzer et al., 2007; Zhang et al., 
2014). Despite these attempts, a reproducible blood gene signature for PD is still 
lacking. 
 
The laboratory of Professor Gustincich has recently carried out the largest study to 
date on gene expression analysis of the peripheral blood of sporadic drug naïve and 
de novo PD patients (Calligaris et al. 2015, in press). This work analyzed 40 sporadic 
PD patients and 20 HCs (“Discovery set”) by taking advantage of the Affymetrix 
platform. Patients were at the onset of motor symptoms and before initiating any 
pharmacological treatment. By applying bioinformatics analysis, gene expression 
profiling was able to discriminate patients from HCs and identified 54 differentially 
expressed genes in blood. Together with neuronal apoptosis, lymphocyte activation 
and mitochondrial dysfunction, already found in previous analysis of PD blood and 
post-mortem brains, they unveiled transcriptome changes enriched in biological 
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terms related to epigenetic modifications including chromatin remodelling and 
methylation.  
I then decided to take advantage of a new technology called nanoCAGE, developed 
by the collaboration between the laboratories of Professor Gustincich and Professor 
Carninci in RIKEN (Japan) (Plessy et al., 2010). Cap Analysis of Gene Expression 
(CAGE) is a technology based on the generation of short sequence tags from the 5’ 
end of full-length cDNAs followed by high-throughput sequencing. When mapped to 
a reference genome, CAGE tags survey TSSs activity of specific promoters and 
measure expression levels on a massive scale (Carninci et al., 2006; Suzuki et al., 
2009). With nanoCAGE, cDNA tags corresponding to the first 27 nucleotides of all 
transcripts are synthesized and identified by next generation sequencing. The number 
of sequencing reads for a defined tag is directly proportional to its RNA template, 
providing a measure of its expression level.  
This technique gives an unbias description of the cellular transcriptome. It can work 
on tiny amounts of RNAs, and allows studying the expression of both polyA+ and 
polyA- RNAs.  
In summary, nanoCAGE is a powerful tool to obtain a snapshot of the blood 
transcriptome of PD patients, analyzing both annotated and previously unidentified 
transcripts. 
We therefore assayed by nanoCAGE the blood transcriptome of 20 PD drug naïve de 
novo PD patients versus 20 HC age and sex matched. 10 million tags were 
sequenced for each sample. 
From the bioinformatic analysis the most up-regulated nanoCAGE tag mapped to 
chr16:173660-174239 region and it was highly induced (50/100 fold) in 30% of PD 
patients.  
As expected from the multi-mapping nature of the tag, it mapped to a repetitive DNA 
region: a minisatellite with a unit length of 29 nt repeated 16 times in the human 
reference genome hg19. This minisatellite is human-specific and it is exclusively 
located in this region. 
While no studies are available to date on this specific minisatellite, it maps in a 
highly studied locus: the alpha-globin genes cluster that regulates α-like globin 
chains expression.  
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This cluster is located in the telomeric region of chromosome 16 (16p13.3) and it 
includes an embryonic gene (ζ), two pseudogenes (θ and αD) and the hemoglobin 
alpha genes (α1 and α2), surrounded by widely expressed genes. 
The main regulatory regions are located about 25-65 kb upstream of the alpha-globin 
genes and they are called Multispecies Conserved Sequences (MCS), called MCS-R1 
to -R4 (Higgs, 2013).  
In particular, MCS-R3 is the nearest regulatory element to the minisatellite, from 
which the distance is about 3 kb, and they both lie in the third intron of the widely 
expressed gene Nprl3. 
By amplifying the minisatellite genomic portion by PCR we discovered that 
individuals present different combinations of two alleles: one with 16-repeats and 
one with 13 of the 29-mer sequence unit.  
We then analysed the identity of the minisatellite variants in the 40 individuals of the 
cohort of the nanoCAGE study. Interestingly, we found that high-tag expression is 
correlated with a heterozygous genome composed of 16/13 repeats while low-tag 
expression is correlated to a homozygous genome (16/16 repeats). 
This result was intriguing since minisatellites have been extensively correlated with 
human diseases (see Introduction) and it is known that the number of repeats could 
influence the level of expression of the nearby genes.  
I thus hypothesized that the minisatellite could influence gene expression acting as 
an enhancer and therefore I performed a luciferase-based enhancer assay in vitro on 
the alleles. However, I didn’t detect relevant activities neither a significant difference 
between the two alleles. 
I then set up a genome-wide association study to look for other genomic loci 
associated to 13-repeats minisatellite conformation. Unfortunately, the analysis did 
not evidence any linkage. 
 
Given that heterozygosity is more frequent in PD compared to HC according to the 
nanoCAGE cohort, I thought that minisatellite allele 13 could be a susceptibility 
marker for PD. 
By genotyping more than one thousand PD individuals and HC we discovered that 
the frequency of heterozygosity is about 20% in both patients and controls. These 
results reject the hypothesis of allele 13 being linked to the pathology. Nonetheless, I 
observed that the allele 13 presented a much lower frequency in nanoCAGE-
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analyzed HCs than in samples from DNA banks. Among the 60 HC from 
Associazione Donatori Sangue Trieste, only 7% were heterozygous. One potential 
explanation is that the frequency depends on the geographical area and ethnic 
composition of the sampled population.  
 
The nanoCAGE study showed that the single HC individual with a 16/13 genotype 
presented the tag expression significantly lower than 16/13 PDs. While one sample is 
clearly insufficient for any scientific conclusion, I hypothesized that the presence of 
the allele 13 might influence gene expression in a disease-dependent manner. This 
would have tremendous consequences since the allele 13 may represent a 
stratification biomarker with diagnostic value.  
Peripheral biomarkers are very much needed in PD since they represent a useful tool 
to stratify patients in order to choose/achieve the best personalized therapy (Precision 
Medicine). For example Chen-Plotkin et al., 2011 showed that epidermal growth 
factor in plasma may be a biomarker to predict cognitive impairment in PD. 
To develop a gene expression assay for the repeat-containing transcript I needed to 
identify its full-length mRNA. To this purpose, I took advantage of the 3’RACE 
technique to isolate the complete cDNA towards the 3’end and then of the 5’RACE 
to confirm its TSS location in the minisatellite sequence.  
Full-length cloning shows that the minisatellite sequence represents an alternative 
5’end of a newly discovered Nprl3 isoform that we called TagNprl3. 
Transcription does not start from the canonical initiator called Inr but from a less 
common core promoter sequence called TCT motif (YC+1TYTYY), which has been 
found to be specific for ribosomal protein coding genes and others involved in 
protein synthesis (Parry et al., 2010). 
This result suggests TagNprl3 might be involved in protein synthesis. 
I then validated the TagNprl3 transcript and designed a specific assay for its 
detection by quantitative TaqMan RT-PCR. I thus analyzed its expression in four 
independent sets of individuals: PD and HC of both 16/13 and 16/16 individuals. 
TagNprl3 expression was higher in 16/13 PDs and HCs individuals revealing an 
allele-dependent high transcription rather than a disease-dependent one. Remarkably, 
minisatellite conformation does not influence Nprl3 canonical isoform 1 expression. 
To our knowledge, this is the first time that a TSS is located in a minisatellite region, 
which variant in turn regulates its expression. A robust literature is available for 
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minisatellites that can influence gene expression when located in the promoter 
region, but that are not part of the mature mRNA. Among them, the transcribed 
minisatellite of the DRD4 gene is located in the third intron but its length does not 
influence the rate of expression or the function of the translated protein (see 
Introduction). In this case, TagNprl3 TSS is located in a minisatellite which is 
partially transcribed (it is part of the 5’UTR) and which length regulates its 
expression. 
In this context I have found intriguing the recent findings on ATRX protein, a 
chromatin-remodelling factor that localizes throughout the genome at G-rich and 
CpG rich sequences including tandem repeats and CpG islands (Law et al., 2010). 
The protein is extensively studied since its mutations are associated to X-linked 
mental retardation with alpha thalassemia. Interestingly, mutant ATRX causes a 
downregulation of alpha globin genes due to its binding to a VNTR located within 
the cluster. In individuals carrying the same ATRX mutation, the degree of 
downregulation is proportional to the VNTR length. 
Therefore, ATRX alters gene expression via an interaction with G-rich repeats while 
it remains unclear how the protein recognizes repeated sequences. Law et al., 2010 
proposed that ATRX might recognize G-quadruplex (G4) structures that are likely to 
form when G-rich sequences are single stranded, as in DNA replication or 
transcription. The G4 structures may interfere with these processes and alter local 
gene expression while ATRX could help resolving such structures. 
An interesting hypothesis to test in the future involves the influence on gene 
expression of ATRX binding to the minisatellite and assuming different binding 
affinities to alleles 16 or 13.  
 
The next question I wanted to ask was whether TagNprl3 transcript is translated into 
protein. Therefore, I cloned its full-length sequence and expressed it in vitro. By 
using an anti Nprl3 polyclonal antibody I was able to detect a 60 kDa protein that 
corresponds to a N-terminal truncated Nprl3 isoform.  
Nprl3 gene was discovered in 1995 by Vyas and colleagues that described its 
sequence and its evolutionary conserved position near the alpha globin cluster.  
Although it is a widely expressed gene and it is highly conserved in metazoa, the 
function of the translated protein remained unclear for years, until 2009 when 
Neklesa & Davis demonstrated that Nprl3 forms a dimer with its homologous Nprl2 
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and together they take part to a complex responsible of mTORC1 inhibition. Nprl3 
expression alterations have been correlated to mTOR pathway perturbation. 
Kowalczyk et al. in 2012 showed that Nprl3 ablation in mouse causes gestational 
death and the perturbation of protein synthesis and cell cycle genes, tightly regulated 
by mTOR. Recently, mTOR activation was found in patients with familial focal 
cortical dysplasia (FCD) as a consequence of Nprl3 gene mutations (Sim et al., 
2015). 
Nevertheless all the published works studied the effect of Nprl3 downregulation and 
nothing is known about the possible effects of its upregulation. 
Since TagNprl3 expression is linked to genotype rather than to PD, I investigated the 
cellular source of this transcript, the presence of the translated protein and the 
biological consequences of TagNprl3 induction in vitro. 
I thus demonstrated that TagNprl3 is expressed in RBC by performing blood 
fractionation followed by RNA and protein extraction. I detected TagNprl3 transcript 
by Real-Time TaqMan RT-PCR comparing high-expressing versus low-expressing 
samples and subsequently I detected its protein products in vivo by western blot, 
demonstrating that TagNprl3 is strongly upregulated in RBCs of 16/13 individuals. 
By taking advantage of immunoprecipitation assays in vitro, we demonstrated that 
TagNprl3, like canonical Nprl3, forms a dimer with its partner Nprl2, despites 
lacking the first 78 aminoacids. 
Interestingly, the longin domain (LD) at the N-terminal found by Levine et al. in 
2013 is not necessary for this interaction since Nprl3 isoform 2, lacking this domain, 
maintain its ability to dimerize with Nprl2. The authors suggest that LDs could act as 
a platform for a GTPase involved in TORC1 signaling. If this is true, TagNprl3 could 
compete with canonical Nprl3. 
By looking for differential function between TagNprl3 and canonical Nprl3, we first 
analysed mTORC1 downstream pathways with WB, discovering TaqNprl3 
overexpression has no effects on autophagy neither on protein synthesis. 
By performing BrdU assays, we demonstrated that TagNprl3 retains the ability of the 
full-length protein to inhibit proliferation, as in Lunardi et al. in 2009. They proposed 
that this is due to Nprl3 interaction with p73, a negative regulator of cell growth and 
involved in embryonic development, cell differentiation and tumor suppression.  
Although TagNprl3 protein influence on mTORC1 activity must be proven, the fact 
that it is overexpressed in RBCs raises intriguing hypothesis on its function. Indeed 
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mTORC1 activity is crucial for RBCs, as demonstrated in mice: blood reticulocytes 
present high mTORC1 activity that could be modulated by iron availability and 
metabolism (Bayeva et al., 2012; Knight et al., 2014; La et al., 2013; Ohyashiki et 
al., 2009). Imbalances in mTORC1 function lead to different types of anemias with 
changes in RBC size, number and hemoglobin content (Knight et al., 2014); 
moreover, in humans the pharmacological activation of mTORC1 can ameliorate 
some types of hereditary anemias (Jaako et al., 2012; Payne et al., 2012). 
Furthermore, a SNP at the Nprl3 gene has been found to be correlated to haemolysis 
in sickle cell anemia (Milton et al., 2012). 
Nprl2 absence in mice severely compromises hematopoiesis (Dutchak et al., 2015) 
since it takes part to the GATOR1 protein complex that inhibits mTORC1, and it 
regulates the uptake and availability of cobalamin. This vitamin is required for 
methionine and S-Adenosyl methionin (SAM) synthesis that are part of important 
metabolic pathways for hematopoiesis (Klee, 2000; Koury and Ponka, 2004). 
More generally, Nprl2 has been shown to be involved in DNA mismatch repair, cell 
cycle signalling, regulation of apoptosis and, importantly, is a candidate tumor 
suppressor gene. Nprl2 expression can be also a marker for malignancy (Otani et al., 
2009). 
On the other hand, the current understanding of Nprl3 function is essentially related 
to its participation to the protein complex GATOR1 inhibiting mTORC1 and to the 
studies investigating the effects of its absence or functional mutations. 
 
In summary, future efforts should be focused on the understanding of the role of 
Nprl3 in cell homeostasis and the effects of its induction in RBCs. This work 
provides hints for Nprl3 protein function in blood and may suggest for the first time 
a link between mTOR and genomic polymorphisms in modifier genes. It will be 
interesting to study the association of these variants with hematopoiesis alterations 
and with cancers. 
Even if we could not correlate minisatellite genotype and TagNprl3 expression with 
PD, it is possible that this marked induction in the blood of 16/13 individuals may 
influence the course of the pathology. In this context, it is particularly intriguing that 
the TagNprl3 binding partner Nprl2 is paying a fundamental role in Vitamin B12 and 
methionine metabolism, a pathway targeted by levodopa, the current symptomatic 
treatment of PD. It will be interesting to evaluate whether 16/16 and 16/13 possess 
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different responses to levodopa pharmacological treatment.  
 
These results are included in a manuscript in preparation entitled “Discovery of a 
human VNTR allelic variant in Nprl3 gene intron that enhances its transcription in 
peripheral blood” (Maria Bertuzzi, Dave Tang, Raffaella Calligaris, Christina 
Vlachouli, Sara Finaurini, Stefano Goldwurm, Gilberto Pizzolato, Piero Carninci, 
Stefano Gustincich). 
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